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Risperidone is an ‘atypical’ antipsychotic and is approved by the USFDA mainly
for the treatment of schizophrenia and symptoms of bipolar disorder. Risperidone (an SDA
or serotonin-dopamine antagonist) has ∼20-fold higher affinity at 5-HT2A receptors over
dopamine D2 receptors, which makes it more efficacious against the negative symptoms of
schizophrenia and less liable to causing extrapyramidal side effects than ‘typical’
antipsychotics.
The major goal of the current investigation was to study the structure of risperidone
and to identify the minimum structural features required for 5-HT2A receptor affinity that
retain antagonist action. The structure of risperidone was systematically deconstructed, and

functional activity studies using calcium imaging in HEK293 cells and a two-electrode
voltage clamp (TEVC) assay in a Xenopus laevis heterologous system were coupled with
radioligand binding affinity studies to achieve this goal. The biological studies showed that
the entire structure of risperidone was not required for activity or affinity at the receptor, as
6-fluoro-[3-(1-methylpiperidin-4-yl)]benz[d]isoxazole was comparable to risperidone in
both affinity and activity.
Next, the structure of risperidone was elaborated to determine the importance of its
left and right “halves” in its actions. The left and the right halves of risperidone were
substituted with those of another antagonist, ketanserin, to give structural hybrids.
Biological studies suggested that the right half of risperidone [i.e., the 6-fluoro-(3piperidin-4-yl)benz[d]isoxazole moiety] might be important for affinity.
In order to assess how the biologically-active compounds interact at the receptor,
homology models of the human 5-HT2A receptor were developed, and docking and
Hydropathic INTeraction studies were conducted. Risperidone seemed to form a bifurcated
hydrogen bond with S159 (TM3), which ketanserin was unable to form. This interaction
might account for high binding affinity at the receptor as it is common to both, risperidone
and 3-[2-(4-(6-fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)ethyl]-2,4-(1H,3H)quinazolinedione.
With the data currently in hand, we can conclude that the entire structure of
risperidone is not required for activity or affinity, and that the right “half” (i.e. the
benzisoxazolyl portion) of risperidone might be influencing activity and affinity at 5-HT2A
receptors.

CHAPTER I: INTRODUCTION

Schizophrenia is a mental disorder currently affecting about 1% of the world’s
population, and is a leading cause of disability, unemployment and suicide in developed
countries.1 Compared to depression, mania and other psychiatric disorders, the documented
origins of schizophrenia are fairly recent (early nineteenth century), although earlier the
disorder might have been referred to in general as ‘madness’.2

A striking property of schizophrenia that distinguishes it from other psychiatric illnesses is
the apparent loss of touch with reality. This manifests in the form of paranoid delusions
and hallucinations (positive symptoms).3 Before the advent of antipsychotics, large mental
institutions were common and patients were locked up – often lifelong, and their
symptoms were suppressed by inducing insulin coma or by the surgical excision of certain
sections of the brain.4 These techniques, though temporarily effective in calming patients,
had disastrous repercussions in the long run.

The discovery of chlorpromazine and the subsequent development of the typical
antipsychotics was a revolution in psychiatry as they alleviated the positive symptoms of
the disorder.5 These typical antipsychotics were dopamine D2 receptor antagonists and
although effective against the positive symptoms, they were ineffective against the apathy

1

and anhedonia (negative symptoms) and cognitive deficits associated with the disorder and
their predominantly dopaminergic activity led to extrapyramidal side effects such as
tremors and rigidity.5

The importance of the serotonergic system was realized after certain 5-HT2A receptor
antagonists such as ritanserin and spiperone exhibited activity against the negative
symptoms of schizophrenia.6 It was established later that an optimum ratio of D2/5-HT2A
receptor affinity (Meltzer’s ratio) was necessary for activity against the positive, negative
and cognitive symptoms; and a higher Meltzer’s ratio correlated with a lower risk of
causing extrapyramidal side effects.7 This led to the development of atypical
antipsychotics, which are dual serotonin-dopamine antagonists such as risperidone.

Risperidone had certain structural features that distinguished it from structurally related
predecessors such as ketanserin and from its atypical contemporaries such as clozapine. Its
high Meltzer’s ratio of ∼20 led to an ideal D2/5-HT2A receptor affinity profile such that
when about 50% of the D2 receptors are occupied, nearly all 5-HT2A receptors are occupied
and this was sufficient for its antipsychotic activity. In addition, it has a gradual occupancy
at D2 receptors, combined with a rapid dissociation rate.8 Thus, risperidone seemed to
possess the perfect features to combat the symptoms of schizophrenia without causing
extrapyramidal side effects.

2

Risperidone has recently demonstrated the ability to crosstalk at the 5-HT2A-mGlu2
receptor heteromer complex, which is a potential novel target for schizophrenia.9 The
purpose of the current investigation is to determine the structural features of risperidone
conferring it with its antagonist activity at 5-HT2A receptors, with the long-term goal of
synthesizing a bivalent ligand capable of targeting the 5-HT2A-mGlu2 receptor heteromer.

3

CHAPTER II: BACKGROUND

A. MENTAL HEALTH AND THE WORLD
1. Current status of mental health in the world:
After years of hiding under the garb of ignorance and superstitions, psychiatry finally came
to the forefront of health science after Delay and Deniker administered chlorpromazine
(thorazine®) (CPZ) (1) (Figure 1) to patients at the St. Anne’s hospital in Paris in 1952.4
Psychiatry has come a long way since the days of moral therapy and barbaric methods such
as insulin coma, convulsive therapy, and pre-frontal lobotomy.4 The National Mental
Health Act of 1946 and the establishment of the National Institute of Mental Health
(NIMH) called for government-sponsored research towards mental illness.10 There has
been progress in every field of psychiatry including development of antipsychotic agents
(Figure 1) to combat schizophrenia-like symptoms and antianxiety drugs (initially referred
to as minor tranquilizers), to antidepressants (initially called psychic energizers).4,11

Research of over three quarters of a century has generated a wealth of research articles;
blog posts and the media have helped propel mental health into public scrutiny, and
communities all over the world are gradually accepting the importance of mental wellbeing.10
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Figure 1. Examples of antipsychotic agents currently on the market.12

The World Health Organization (WHO) has charted the ‘Comprehensive Mental Health
Action Plan 2013-2020’ with the aim of ensuring the worldwide availability of mental
health resources, and released the WHO Mental Health Atlas starting from 2001 and
5

updated in 2005, 2011 and 2014, that measures the progress of member states in realizing
the goals of the plan. According to the WHO Mental Health Atlas 2014, out of the 131
responders of the 194 WHO members, about 68% had a mental health policy or a plan for
mental health and 51% have a self-contained mental health law.13

As per the report there is a huge gap in the conditions existing among the countries based
on per capita income. As regards availability of resources, there is a huge gap in low- and
high-income countries. The situation is as dire as 1 mental health worker per 100,000
population in low-income countries to more than 50 per 100,000 population in highincome countries.13,14 This disparity seems to continue even in sources of funding for
treatment of mental health conditions and the median mental health expenditure per capita.
Government is the main source of funding in 79% of the countries; however, out-of-pocket
is also the main source of funding for 18% of the countries, suggesting either a dearth in
funds or its unequal distribution.13 The median mental health expenditure per capita is as
low as $1.53 and $1.96 for low- and middle-income countries, respectively, and $58.73 for
high-income countries.13,14

Over the years there has been a greater focus on community-based mental health services
(psychiatric wards in general hospitals) over large mental institutions.15 These services
promote rehabilitation and gradual incorporation of recently discharged, chronically
mentally disturbed individuals into society. The intention is to create a support system for
the affected people and is also one of the goals of the ‘Comprehensive Mental Health
6

Action Plan 2013-2020’.13 Accordingly, there has been a steady decline in the number of
mental hospitals since 2011 and a pronounced increase (around 60%) in the number of
psychiatric wards in general hospitals.13

Studies have shown that social acceptance has gone a long way towards the
reestablishment of mental health patients.16 The stigma associated with these disorders,
stemming not only from ignorance and indifference but also from intolerance, leads to a
vicious circle of discrimination in terms of basic necessities such as treatment, housing,
employment, which then leads to a loss of self-esteem, resistance to treatment and relapse,
ultimately making it difficult for people to recover.16,17 Literature suggests that in the
United States, about 46% of homeless adults in shelter homes are living with severe mental
illness, about 90% of suicidal deaths have a strong background of mental illness and an
unbelievably increasing number of people are deemed disabled due to mental diseases
every year and most of them are in the prime years of their lives.18,19 However, there is
hope and there are global efforts to reduce misconceptions that people might harbor. The
Japanese society of Psychiatry and Neurology recently changed the term for schizophrenia
“Seishin-Bunretsu-Byo” which translates to “Split-Mind-Disease” and has replaced it with
“Togo-Shitcho-Sho” which means “Integration Disorder.”17 Programs are being
established with the intention of educating the public, protesting against possible
discrimination, and promoting direct contact between the people suffering and the
public.16,17 Psychiatry, as a practice, has seen a number of changes in recent times. It has
now shifted gears towards clinical neuroscience, attempting to bring the basic etiology and
7

pathophysiology of the disorders to the forefront, hopefully giving us a better picture of the
situation.20,21

2. An overview of antipsychotic therapy in the United States:
In the United States, mental disorders exact a huge toll on the economy.14 The NIMH has
estimated that 1 in 4 Americans suffers from some form of mental disorder. Schizophrenia
affects about 1%, and bipolar disorder affects about 2.6%, of the adult population in the
US.3 In 2010, schizophrenia alone was responsible for nearly 400,000 hospitalizations.22

There are two groups of antipsychotic drugs currently on the market to treat schizophrenia
(Figure 1).23,24 The ‘first generation’ or typical antipsychotics, previously called
neuroleptics, targeted dopamine D2 receptors and are effective against the positive
symptoms of schizophrenia, but, inevitably, led to Parkinson-like extrapyramidal side
effects (EPS).5 This class of agents is typified by CPZ (1) (Figure 1). The ‘second
generation’ or atypical antipsychotics are mostly dual dopamine D2 and serotonin 5-HT2A
receptor antagonists and/or inverse agonists effective against the positive as well as
negative symptoms and cognitive deficits.24–26

The atypical antipsychotics were initially thought of as being devoid of the side effects
caused by typical antipsychotics; however, recent studies have shown that long-term use of
these agents can also cause motor side effects (due to their high affinity at dopamine D2
receptors), in addition to metabolic disorders and sexual dysfunction.27–29
8

The 1990s ushered in a new era in the field of antipsychotics with a number of atypical
antipsychotic drugs being approved for clinical use.30 Although mainly indicated for the
treatment of schizophrenia, these agents are now gaining importance in the management of
other psychiatric conditions such as bipolar disorders and depression as well.31,32

Clozapine (2) (Clozaril®) (Figure 1) was the first atypical antipsychotic drug to be
approved for the treatment of schizophrenia.30 However, it was associated with serious
blood conditions such as agranulocytosis, and is currently prescribed only for treatmentresistant schizophrenia with indications of regular monitoring of blood cells.33–35

Risperidone (3) (Risperdal®) (Figure 1) was introduced by Janssen-Cilag in 1993.24 In
addition to monotherapy in schizophrenia, it is now also used as a clozapine-adjunct in
clozapine-resistant patients of schizophrenia and schizoaffective disorders.36 It is,
unfortunately, associated with metabolic disorders, weight gain, prolactin elevation, and is
contraindicated in patients with dementia-related psychosis.37

This was followed by olanzapine (4) (Zyprexa®) (Figure 1), which was introduced by Eli
Lilly in 1996.23 It appeared to be sparing of agranulocytosis caused by its structural
predecessor, clozapine, and there was minimal elevation of prolactin.38 However, there
were reports of transient increases in serum transaminases (indicative of liver damage) and
increased appetite that seemed to be of concern.39,40 Olanzapine is approved for use in the
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United States as maintenance therapy for schizophrenia, as an adjunct to fluoxetine in
refractory depression, and in bipolar disorder.41,42 Quetiapine (5) (Seroquel®) (Figure 1),
was developed by AstraZeneca and was introduced in the Unites States in 1997.23 It is in
clinical use for the treatment of schizophrenia, bipolar depression, and recently, for
generalized anxiety disorder.43,44 Ziprasidone (6) (Geodon®) (Figure 1), was introduced in
2001 and, although significantly helpful against motor and metabolic side effects common
with the other atypicals, ziprasidone had a tendency to cause Qtc prolongation leading to
cardiac events and, as with risperidone, is contraindicated in dementia-related psychosis.23

Paliperidone (7) (Invega®) (Figure 1) is a metabolite of risperidone and an antipsychotic
agent in it’s own right.45 It was approved for clinical use in 2006 and shares most of its
side effects with risperidone.46

A new class of atypical antipsychotics, termed ‘third generation’ antipsychotics, was
introduced in the mid-2000s.47 Aripiprazole (8) (Abilify®) (Figure 1), an example of this
class, was ranked the best-selling drug in the United States from the period of October
2013 to September 2014.48 It differs from the other atypical antipsychotics in being a
partial agonist at D2 receptors – sparing EPS, and a partial agonist (instead of an
antagonist) at 5-HT2C receptors, thus avoiding the weight gain.49,50 It is used for the
treatment of schizophrenia, bipolar I disorder, depression, and anxiety disorder.51
Haloperidol (9) (Haldol®) (Figure 1) a typical antipsychotic developed in 1958, is still used
clinically and accounted for 5% of the market prescriptions in 2011.23,48
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Despite this clinical progress, there is still a sense of uncertainty in whether long-term use
of antipsychotic medications really helps patients regain their independence and,
eventually, lead a normal life.52

3. Are antipsychotics helpful in the long run?
“Could our drug-based paradigm of care, in some unforeseen way, be fueling this modern
day plague?” questions Robert Whitaker in his book ‘Anatomy of an epidemic: Magic
bullets, psychiatric drugs and the astonishing rise of mental illness in America’ when
examining the growing pandemic of mental illness in the United States despite extensive
biomedical facilities and drugs to combat the diseases.4

The modern belief of psychiatry is to maintain schizophrenia patients on antipsychotic
drugs long after even the acute stage of the illness has been relieved.52 Treatment of
schizophrenia can be divided into three stages: an acute stage of psychosis, usually
accompanied by hospitalization, a second stage that includes the next 2-3 years after the
initial episode, and thereafter a third stage where active symptoms may or may not
persist.53,54 The question many in the scientific community have raised is whether to keep
patients on long-term medication – most of which carry their own plethora of side effects,
or to discontinue medication gradually.52,55 The scientific community is also divided over
whether antipsychotics have any efficacy in the long run, or simply make people so
dependent that they are unable to resume an unaided life.4,56,57
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In his book, Whitaker presents case studies of two scenarios: first, of people who have
discontinued (mostly stealthily) medication and have made significant progress both
personally and professionally, and second, of people who have come so far on the drugs
that they seem to be functioning solely due to them. However, people on the drugs, while
tolerating the side effects, still wonder what life would have been like while medicationfree.4

Short-term double-blind studies have provided positive reviews about the effectiveness of
antipsychotic use, with some patients even showing remission.52 However, most of the
long-term studies are often a reflection of short-term discontinuation studies of the
medication – wherein the first 6-10 months after drug discontinuation, patients either
relapse or remain stable. Interestingly, relapse rates are much lower for patients who
remain stable during these 6-10 months off-medication.52

Long-term longitudinal studies are in contradiction to the positive short-term studies and
some studies even question the long-term efficacy of drug treatment.52,56,57 In a 15-year
longitudinal study, Harrow and Jobe52 reported that only about 40% of schizophrenia
patients show one or more periods of recovery. More than 50% of the patients had
recurring episodes of psychosis and some had psychotic episodes that were serious enough
to affect normal functioning.57 Another 20-year, multi-follow-up longitudinal study
reported that a substantial percentage of schizophrenia patients who were no longer on
antipsychotic therapy were psychosis-free, had a lower relapse rate and recovered faster,
12

suggesting that, perhaps, not all schizophrenia patients need to be on drug-therapy for their
entire lives.56 This shows that while long-term treatment with antipsychotic drugs does not
guarantee recovery, the prognosis depends on the individual.58 The risks (which are
numerous and dangerous)-benefit ratio of antipsychotic drug therapy need to be weighed
carefully before pharmacotherapeutically dealing with this complicated and multifaceted
disorder.58,59

4. Therapeutic strategies and those under development:
Most current efforts are mainly directed towards improving the pharmacokinetics and sideeffect profiles of currently marketed antipsychotic drugs.23,28 While most drugs target
dopamine D2 receptors, with varying degrees of binding affinity and efficacy (with most
acting as D2 antagonists), efforts are being directed towards novel therapeutic targets for
antipsychotic therapy.9,60,61 Some clinically-relevant developments are discussed.

a. Improvements over current antipsychotic drugs:
The major grievances against currently marketed atypical antipsychotics are their tendency
to cause significant weight gain, metabolic disorders, cardiac problems and sedation,
among others.58 These problems might be a result of additional multi-receptor interactions,
such as those with 5-HT2C, H1, M1-M5 and α1-adrenoceptors.23,39 Structural modifications
have attempted to achieve selectivity and avoid off-target interactions.
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Iloperidone (10) (Fanapt®) (Figure 2) was approved by the USFDA in 2009 and is
structurally related to risperidone (3).23,62 It has low affinity for H1 histamine and
muscarinic receptors, so there is a lower chance of weight gain, sedation and metabolic
disorders caused by the older atypical agents.23 However, its affinity for α1-adrenoceptors
is sufficient to cause Qtc prolongation. Oral iloperidone is now recommended for the acute
treatment of adults with schizophrenia.55
N O

N O
O
H 3C

N

O

F

N

N

OCH3

N

F

CH3

O

Risperidone (3)

Iloperidone (10)

Figure 2. Structure of iloperidone in relation to risperidone.23
Lurasidone (11) (Latuda®) (Figure 3) is structurally similar to ziprasidone (6) and was
approved for the treatment of schizophrenia in 2010.23,48 Apart from 5-HT2A and D2
receptors, lurasidone is also a 5-HT7 receptor antagonist that has been shown to be helpful
against the cognitive deficits of schizophrenia.63 Also, lurasidone has reduced affinity at
α1-adrenoceptors and 5-HT2C receptors, and no affinity at H1 histamine or M1 muscarinic
receptors leading to an improved cardiovascular profile, and a low liability of weight gain
and sedation.23,63
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Figure 3. Structure of lurasidone in relation to ziprasidone.23

Another novel class of compounds that was actually developed in the 1980s but that has
only recently been clinically explored is what have been termed ‘dopamine stabilizers.’64
The clinically approved atypical antipsychotic drug aripiprazole (8) (Figure 1) belongs to
this class.49 These compounds are either dopamine partial agonists or antagonists,
depending on basal dopaminergic tone, and have the ability to interact with D2 dopamine
receptors just enough to decrease the hyperdopaminergia of schizophrenia without carrying
the risk of hypodopaminergia.49,64 Studies have shown that even after 80% occupation of
D2 receptors, there are minimal chances of EPS.65 This group of compounds is being
extensively researched and some of them have even reached clinical trials.23
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b. Non-dopaminergic and non-serotonergic targets:
Atypical antipsychotics are effective against the negative symptoms and cognitive deficits
of schizophrenia in addition to the positive symptoms but their overall advantage over
typical antipsychotics is only modest and they also come with their own side effects.66 In
such scenarios, there is an acute need to explore other therapeutic targets.

i. Glutamatergic drugs: The ‘NMDA hypothesis of schizophrenia’ (which will be discussed
later) was established in 1995 based on the observation that NMDA receptor antagonists
such as ketamine and phencyclidine (PCP) mimic not only the positive symptoms, shown
by amphetamine, but also the negative and cognitive symptoms of schizophrenia.67 The
metabotropic glutamate (mGlu) receptors belong to class C G-protein coupled receptors
(GPCRs) and consist of 8 subtypes of which mGlu2 and mGlu3 (and recently, mGlu5) have
been extensively studied with regards to schizophrenia (Table 1).68

Table 1. Classification of metabotropic glutamate receptors adapted from Swanson et al.69
Family receptor
Group 1

Coupling

Localization

mGlu1

Excitatory – Gαq coupled

Postsynaptic at
glutamatergic synapses and
cerebellar localization in
granular cell and parallel
fibre layer

mGlu5

Excitatory – Gαq coupled

Postsynaptic at
glutamatergic synapses, also
in glial cells. High
expression in forebrain
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regions such as
hippocampus and amygdala
Group II

mGlu2

Inhibitory – Gαi/o coupled

Largely presynaptic
glutamatergic localization,
also high expression in
forebrain regions such as
hippocampus and amygdala

mGlu3

Inhibitory – Gαi/o coupled

Largely presynaptic
glutamatergic localization,
also high expression in
forebrain regions such as
hippocampus and amygdala

mGlu4

Inhibitory – Gαi/o coupled

Both pre- (cerebellar parallel
fibres) and postsynaptic
localization

mGlu6

Inhibitory – Gαi/o coupled

Expression confirmed only
in retinal bipolar ON cells.

mGlu7

Inhibitory – Gαi/o coupled

Only presynaptic inhibitory
mGlu localized to active
zone of synapses

mGlu8

Inhibitory – Gαi/o coupled

Largely presynaptic
glutamatergic localization,
also high expression in
forebrain regions such as
hippocampus and amygdala

Group III
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Evidence from the ability of mGlu2/3 orthosteric agonists [e.g. LY354740 (12) and
LY379268 (13)] (Figure 4) to inhibit phencyclidine (PCP)-induced positive and negative
symptoms led to mGlu2/3 receptors to be studied as novel targets for drug development.68
However, since the orthosteric site of GPCRs in general is highly conserved among all the
subtypes, it necessitated development of selective agents and, hence, positive allosteric
modulators (PAM) of mGlu2/3 were investigated. A few examples of clinically relevant
mGlu2 PAMs are LY487379 (14) (the first identified selective mGlu2-selective PAM)
(Figure 4), biphenylindanone-A (BINA) (15) and JNJ-40411813 (16). JNJ-40411813 (16)
(Addex and Janssen) and ADZ8529 (17) (AstraZeneca) (structure undisclosed) have
reached clinical trials (Figure 4).23,68-70
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Figure 4. Some agonists and PAMs at mGlu2 receptor with antipsychotic activity in
preclinical and/or clinical studies.23,68
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ii. Phosphodiesterase (PDE) inhibitors: These are inhibitors of the intracellular second
messengers 3,5-cyclic adenosine monophosphate (cAMP) and 3,5-cyclic guanosine
monophosphate (cGMP). Specifically, inhibitors of the subtype PDE10A, which is located
primarily in the brain and the testes in mammals has been extensively studied and PF2545920 from Pfizer has been identified as a clinical candidate for the treatment of
schizophrenia.23,71

iii. Glycine transporter inhibitors: Following the NMDA hypothesis, one more avenue
being explored to enhance glutamatergic signaling, especially to overcome the negative
symptoms of schizophrenia, was to reinforce the effects of the NMDA receptor co-agonist
glycine. This was achieved by the inhibition of the glycine transporter-1 (GlyT-1) on glial
cells and is being examined clinically.72

B. CONDITIONS ASSOCIATED WITH SEROTONIN IMBALANCE
5-Hydroxytryptamine (5-HT) or serotonin (18) (Figure 5) was first identified as a
vasoconstrictor in mammalian serum in 1948 and was also found in gastric mucosa, and to
have an excitatory effect on intestinal smooth muscles.73,74 Thereafter, its presence in the
central nervous system was established in invertebrates, rodents, and eventually in several
species of mammals.73 The effects of modulating 5-HT levels (through activation of 5-HT
receptors) by pharmacological agents such as lysergic acid diethylamide (LSD) (19)
(Figure 5), led to the conclusion that 5-HT plays a key role in behavior.75,76 It is now
known that 5-HT is not only responsible for neuronal development, memory, emotional
19

processing, depression, anxiety, schizophrenia, appetite, sleep and sexual behavior, but
also for platelet aggregation and regulation of smooth muscles of the heart.77–80

An increase and decrease of 5-HT can have profound effects on the body and the most
evident result is on behavior. A few clinical effects of 5-HT imbalance on behavior are
discussed.
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Figure 5. 5-HT and representative structures of classical hallucinogens.81

20

1. Psychosis due to 5-HT agonists and /or hallucinogens:
In order to pinpoint the origin of the effects he experienced after accidental chemical
exposure in his laboratory, Albert Hofmann, a natural products chemist at Sandoz
Pharmaceuticals in Basel, Switzerland, had deliberately self-administered 0.25 g of dlysergic acid diethylamide (LSD) in 1943.81,82 After a period of 40 minutes, his journal
entry reported: “slight giddiness, restlessness, difficulty in concentration, visual
disturbances, laughing”.82 This was followed by a loss of time, disorganized perception of
space, dissociation, alternating restlessness and paralysis; and visual deformation that
lasted hours after the other symptoms had abated.82

Psychosis is an abnormal perception of reality (as described above) and can manifest itself
as hallucinations, delusions, altered consciousness, delirium, cognition problems, and in
certain cases, even death.81 Hallucinogens (classical hallucinogens and dissociatives) bring
about these changes and are mostly used for their recreational potential, in certain religious
experiences (where they are also referred to as entheogens), and are now increasingly
being studied with respect to psychiatric diseases such as schizophrenia.81,83

Classical

hallucinogens

mainly

belong

to

two

main

chemical

classes:

the

indolealkylamines and the phenylalkylamines (Figure 5). The indolealkylamines include
LSD (19), N,N-dimethyltryptamine (DMT) (20), psilocin (21), and the phenylalkylamines
include mescaline (22), 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) (23),
and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (24).83
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After the almost simultaneous discovery of 5-HT and LSD, initial investigations found that
LSD (19) interacted with 5-HT receptors to cause certain behavior changes, and the
striking structural similarities between 5-HT and LSD warranted further examination when
it was thought that 5-HT could be responsible for the actions mediated by LSD.76

It can be concluded from radioligand binding work and studies on animal models such as
drug discrimination (with DOM), head-twitch behavior, startle reflex, conducted in the
past by our laboratory and several others that 5-HT is indeed involved in the mechanism of
action of both classes of hallucinogens with 5-HT2A receptors (referred to as 5-HT2 at that
time) being the key site of action.78-80

LSD (19) was found to be a non-selective low efficacy agonist (or a partial agonist) at
5-HT2A and 5-HT1 receptors.84 In fact, drug discrimination studies conducted by Glennon77
have established that there is a correlation between the ED50 values of the drugs and their
affinity at the 5-HT2A receptor.85 Additionally, studies with antagonists selective for 5HT2A and 5-HT2C, revealed that this hallucinogenic property is due to 5-HT2A and not 5HT2C receptors.86,87 The effects of these serotonergic hallucinogens are dose-dependent and
resemble the earliest phases of schizophrenia, which include changes in mood, thought,
intuition, perception of self and euphoria.88,89 The predominantly visual hallucinations
brought about by these agents recreate those experienced in the acute stages of the disease,
that become more auditory as the disease worsens. This is one of the tenets of the
22

‘serotonin hypothesis of schizophrenia’ and the effects of serotonin hallucinogens have
been used to generate models of schizophrenia for research.89,90

Activation of the 5-HT2A receptor in the prefrontal cortex leads to an increase in the
excitatory postsynaptic potentials (EPSP) in the apical dendritic region of layer V
pyramidal cells which indicates a release of glutamate.91 This has been supported with
mGlu2/3 agonists and AMPA/kainate glutamate receptor antagonists.91,92 NMDA receptor
antagonists such as PCP (25) and ketamine (26) (Figure 6) have been shown to recreate not
only the positive symptoms of psychosis (such as those mediated by the serotonergic
hallucinogens) but also the negative symptoms (depression, anhedonia, social withdrawal)
and cognitive deficits of schizophrenia.93 This has given rise to the ‘NMDA hypothesis of
schizophrenia’ and these models are considered to better depict the overall symptoms of
schizophrenia.92
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Figure 6. NMDA receptor antagonists capable of producing schizophrenia-like
symptoms.81,92
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2. Depression:
Depression is a chronic, persistent mood disorder characterized by anhedonia, feelings of
emptiness, worthlessness, lack of concentration, fatigue, increased or decreased appetite
and an inexplicable need to ‘escape’.94 Depression can be life threatening and is
responsible for an increasing number of suicides across the world.95 Evidence has pointed
towards genetic (40-50% risk) as well as non-genetic factors, such as childhood trauma,
stress, bereavement, and major lifestyle changes, in the pathophysiology of the disease.94,95

Reserpine was found to mediate depletion of monoamine neurotransmitters and produce
depression-like symptoms and is believed to be the foundation of the monoamine
hypothesis of depression.96 The first two drugs showing antidepressant-like activity (Figure
7) were discovered rather serendipitously. Iproniazid (27) and imipramine (28) (Figure 7)
were obtained as a part of antituberculosis and antihistamine research, respectively, and
were found to dramatically elevate the moods of hospitalized patients.96

These drugs, initially called as ‘psychic energizers’4, were seen to increase the synaptic
levels of 5-HT and norepinephrine (NE) by two different mechanisms: Imipramine (28)
inhibited the reuptake of 5-HT, while iproniazid (27) inhibited monoamine oxidase
(MAO), the enzyme responsible for metabolizing 5-HT and NE.96,97 Imipramine (28) has
led to the development of several classes of marketed drugs inhibiting the reuptake of 5HT and NE such as tricyclic antidepressants [amitriptyline (29)], ‘selective serotonin
reuptake inhibitors’ (SSRIs) [fluoxetine (30)], ‘norepinephrine reuptake inhibitors’ (NRIs)
24

[nortryptyline (31)] and ‘dopamine reuptake inhibitors’ [bupropion (32)] (Figure 7).98–100
The discovery of iproniazid (27) delivered another class of antidepressants called the
monoamine oxidase inhibitors (MAOIs) [isocarboxazid (33)] (Figure 7).101,102

These drugs were developed based on the monoamine hypothesis of depression – that
depression is caused by a deficiency of 5-HT and/or NE (and possibly, DA).91 However,
this hypothesis could not explain why it took 2-4 weeks before activity of antidepressants
was evident and research was extended to receptors and second messenger signaling
pathways, mainly related to 5-HT.94,96 Different regions of the brain such as the
hippocampus and the prefrontal cortex, amygdala, nucleus accumbens and the
hypothalamus have been postulated to be involved in the cognitive problems, the lack of
pleasure and the loss of appetite, reminiscent of depression.103,104

Therapeutic strategies such as deep brain stimulation are practiced for certain treatmentresistant depressions.94 Also, novel therapeutic targets such as the organic cation
transporters (OCTs) are currently being explored to account for the fact that the available
antidepressants, which mainly target the serotonin transporter (SERT), fail to provide relief
to a considerable percentage of patients.105
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Figure 7. Antidepressants of the past and of the present.94,99,100,102,106

3. Anxiety disorders:
The first antianxiety agent was also discovered by chance during drug development for
another therapeutic target.107 The first antianxiety drug was meprobamate (Miltown®) (34),
introduced by Wallace laboratories in 1955, and it was a descendent of mephenesin (35),
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which was discovered for its tranquillizing and muscle relaxant properties, during
antibiotic research (Figure 8).107
O
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CH3
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Meprobamate (34)

Mephenesin (35)

Figure 8. The first antianxiety agents.107,108

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5), “anxiety disorders include disorders that share features of excessive fear and
anxiety and related behavioral disturbances”.109 The disorder is characterized by fear of
certain future events and the anticipation of reacting to them.109,110 Anxiety disorder is a
class of disorders, each having its own specific trigger. The DSM-5 further classifies
anxiety disorders into the following: separation anxiety, selective mutism, specific phobia,
social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder and
substance/medication induced anxiety.109

Recent neuroimaging studies have implicated a role of the amygdala, different regions of
the orbitofrontal cortex, anterior cingulate, parietal and occipital cortices, in the
pathophysiology of anxiety disorders.111 There is evidence that 5-HT1A receptors are
involved in the perception of fear-related cues from studies conducted on homozygote as
well as heterozygote 5-HT1A knockout mice.112 5-HT1A receptors are located
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presynaptically (on serotonergic neurons in the raphe nuclei) and postsynaptically (on
glutamatergic and GABAergic pyramidal neurons in the limbic, frontal and entorhinal
cortices).112,113 Studies on transgenic mice have elicited a role of the postsynaptic 5-HT1A
receptors located in the forebrain to modulate anxious behavior and 5-HT1A receptor
knockout mice show resistance to benzodiazepine (common medications for anxiety)
treatment.112,114

5-HT1A receptors also play a role in the effect of SSRIs (first line of treatment) in anxiety
treatment.115,116 In fact the 5-HT1A receptor antagonist pindolol hastens the action of SSRIs
by preventing the inhibitory action of 5-HT1A autoreceptors that has been shown to delay
the onset of action of SSRIs in humans.112,117 To further bolster this observation, positron
emission tomographic (PET) examination with a radiolabelled selective 5-HT1A antagonist
WAY-100635 has shown that there is a negative correlation between 5-HT1A binding
affinity and anxiety scores, and suggested a role of partial agonists at 5-HT1A
(postsynaptic) receptors in the treatment of anxiety.118

The most commonly prescribed antianxiety agents for generalized anxiety disorder, panic
disorder and social anxiety include the SSRIs and the SNRIs such as sertraline (36),
escitalopram (37), paroxetine (38) (SSRIs), and venlafaxine (39) (SNRI), respectively
(Figure 9).116 Benzodiazepines such as alprazolam (40) (Figure 9) are still used, however,
they are associated with side effects such as sedation, physical dependence and impaired
concentration. They also carry a risk of withdrawal symptoms and rebound anxiety.116,119
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4. Schizophrenia:
The symptoms of schizophrenia become evident as hallucinations (initially visual and then
progressing to auditory), delusions and thought disorders (these are called as positive
symptoms), social withdrawal, apathy, lack of affect and catatonia (these are known as
negative symptoms); and cognitive and decision-making impairments (see Figure
11).91,120,121 The genetic risk of schizophrenia is quite high and it is known that there is a
50% chance for the identical twin of a schizophrenia patient to develop the disease. The
type of household environment during childhood (abusive or emotionally distant parents)
can also contribute.122
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Schizophrenia is neurodevelopmental rather than neurodegenerative in nature, suggested
by the absence of inclusion bodies or gliosis, reminiscent of neurodegenerative diseases.123
It has a varied phenotype and is subjective; hence modeling schizophrenia as a whole in
animal models has been difficult.124 However, animal models of psychosis (e.g. LSD and
PCP) have been successful to an extent, in recreating the positive and negative symptoms,
and have been helpful in determining the brain regions affected.89,92 Neuroimaging and
pharmacological advances have supported this and although we are far from completely
solving the mystery of schizophrenia, we now know that the dopaminergic, serotonergic,
glutamatergic and the GABAergic systems are involved (Figure 10).120,125
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Figure 10. The neural circuits involved in schizophrenia, adapted from Freedman, R.120

a. Symptoms and neuroanatomical changes:
Schizophrenia as a disease can be divided into three stages: the prodromal stage, the
acute/active stage and the residual stage.92 The outward symptoms (Figure 11) that help in
diagnosis generally appear in the mid-20s.120 However, the actual onset of the disease (the
prodromal stage), which can be as early as in the teens, often gets shrouded under the guise
of the emotional and physical changes of adolescence and adjustment to early adulthood.122
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ANHEDONIA
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THOUGHTS
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COGNITIVE DEFICITS
SHORT TERM MEMORY
DEFICITS

Figure 11. The three major symptoms of schizophrenia.92,121
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One of the hypotheses to explain the perceptional abnormalities (hallucinations) and an
inability to differentiate between the internal ‘voices’ and extraneous environmental
stimuli (contributing to delusions) is hyperactivity of the thalamus.125 The thalamus is
responsible for filtering sensory input and is under an inhibitory influence of GABAergic
neurons. This inhibition of the thalamus by GABAergic neurons is controlled by dopamine
D2 receptors.125,126 An abnormally active dopaminergic system can lead to disinhibition of
the thalamus, which is now unable to filter out information, rendering the patient incapable
of discerning the ‘real’ from the ‘fabricated’.125,127

In schizophrenia, the Glu-GABA-Glu-DA pathway (Figure 10) is impaired leading to an
overactive limbic dopaminergic system.128 In the non-psychotic brain, the Glu neurons
from the thalamic sensory relay nucleus (Figure 10) are connected to a smaller GABAergic
interneuron that has an inhibitory influence on the glutamatergic cortical pyramidal neuron,
leading to a lower firing rate. This regulates the dopaminergic output in the limbic system
(Figure 10).120,125 However, compromised NMDA receptors on the GABAergic
interneuron prevent GABA from exerting its inhibitory action on the cortical pyramidal
neuron. The result is an overdose of dopamine in the limbic system and this can lead to
psychosis.128 There is also a failure of the inhibitory interneurons and the inhibitory
neurotransmitter GABA, leading to impaired synaptic connections between cortical and
pyramidal neurons.125
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There are certain striking neuroanatomical changes observed in the schizophrenic brain
such as a marked decrease in the migration of neurons to the cortex from the underlying
white matter, white matter disorganization in the prefrontal cortex and lower pyramidal
cell density.123,125,129 A hallmark of schizophrenia, which is also present in first-episode,
non-medicated patients, is enlarged ventricles (especially third and lateral ventricles) and
diminished volume of the hippocampus and the superior temporal cortex.123 There is a
distinct volume reduction in the frontal lobe, especially in the prefrontal and orbitofrontal
regions.130 Abnormalities in the basal ganglia and thalamus have also been reported. All
these could contribute to the negative symptoms and the cognitive deficits of the
disorder.125,130,131

Although all aspects are not hereditary, there is increasing evidence of a pre-developmental
lesion in the brain, which can interact with certain environmental stressors and this in
already predisposed people can precipitate the onset of the disease.122,123

b. The dopamine hypothesis of schizophrenia:
The dopamine hypothesis of schizophrenia initially stemmed from the discovery that
antipsychotics such as CPZ (1) elicited their effects by decreasing DA concentration in the
mesolimbic region of the brain, that is, they function as DA receptor antagonists.132 In fact
it has been shown that antipsychotic potency is related to the binding affinity of
antipsychotic agents at DA receptors.131
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This was followed by the observation that stimulants such as amphetamine could lead to
effects quite similar to the positive symptoms of schizophrenia.131,133 The dopamine
hypothesis postulated that schizophrenia is caused by overstimulation of dopaminergic
receptors in the mesolimbic region (leading to hallucinations and delusions) and a lack of
dopamine at the nucleus accumbens leading to the anhedonia and lack of motivation.132

The dopamine hypothesis that gained ground during the 1960s led to a thorough
investigation of the dopaminergic tracts in the brain. It was shown that stimulation of DA
receptors in the nigrostriatal pathway by amphetamine led to stereotyped motor effects,
and inhibition of these receptors by the antipsychotic agents led to the extrapyramidal side
effects commonly experienced with these agents.132 This further bolstered the hypothesis.

However, it soon came to light that antipsychotic agents were only effective against the
positive symptoms and had little, if any, effect against the negative symptoms and
cognitive deficits.92,133 Atypical antipsychotic drugs, especially clozapine (2) and
risperidone (3), had greater affinity towards 5-HT2A receptors over D2 receptors, a faster
dissociation rate at D2 receptors, and could help against the positive as well as the negative
symptoms of schizophrenia.134 Additionally, they also had a lower tendency for causing
extrapyramidal side effects.135

Thus, the dopaminergic system could not explain all the parameters of the disease and the
serotonin hypothesis of schizophrenia came along.
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c. The serotonin hypothesis of schizophrenia:
5-HT and psychosis have been linked since the almost simultaneous discovery of LSD (19)
and 5-HT (18) in the late 1940s.80 As discussed earlier (section B), research on the
serotonergic system has evolved hand-in-hand with studies on hallucinogens such as LSD
(19), DMT (20), mescaline (22), and DOM (23), which are agonists and/or partial agonists
at 5-HT receptors, 5-HT2A in particular.84 The hallucinations and bizarre experiences
created by these hallucinogens were very similar to the positive symptoms of the initial
stages of schizophrenia.92 The serotonin hypothesis postulated that hyperactivity of 5-HT
in the cerebral cortex and the locus ceruleus (Figure 10) is responsible for schizophrenia.91

The first atypical antipsychotic, clozapine, further supported the serotonin hypothesis.
Unlike typical antipsychotics such as CPZ (1) and haloperidol (9), it was effective against
the positive, negative, as well as cognitive symptoms of schizophrenia and did not result in
EPS that was a hallmark of classical antipsychotic treatment.30,134,135 The atypical
antipsychotics had a higher affinity at 5-HT2A receptors than at dopamine D2 receptors, and
acted as dual serotonin-dopamine antagonists.136

MRI and PET imaging studies of the cerebral cortex of schizophrenia patients revealed
certain neuroanatomical changes in the serotonergic system.131 Schizophrenia has been
associated with a hyperactive dorsal raphe nucleus (DRN) (Figure 10) and overdriven
serotonergic signaling to the cerebral cortex, especially in the anterior cingulate nucleus
(ACC) and the dorsolateral frontal lobe.91 Post mortem brain samples from schizophrenia
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patients have shown an increase in 5-HT, especially in the putamen, globus pallidus,
nucleus accumbens and the basal ganglia.131 There was a decrease in 5-HT in the
hypothalamus, medulla oblongata, and hippocampus.131,137 This was accompanied by a loss
of grey matter in the ACC, potentially explaining the decreased utilization of ATP in the
frontal lobe.91

Although the atypical antipsychotics are certainly more sparing in their EPS-causing
liability, they have only a modest efficacy over the typical antipsychotics, especially with
regard to the negative symptoms, and a considerable number of patients did not respond to
treatment.68,138 The psychosis generated by NMDA antagonists such as PCP (25) and
ketamine (26) produced the entire spectrum of symptoms and model the disease much
better.92 This focused attention on the role of glutamate in the pathophysiology of
schizophrenia.
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d. The NMDA hypofunction/glutamate hypothesis of schizophrenia:
The complete clinical syndrome of schizophrenia captured by NMDA receptor antagonists
such as PCP and ketamine is the foundation of the glutamate hypothesis of schizophrenia
that was put forward by Olney and Farber in 1995.68,92

Classical

hallucinogens

such

as

LSD

and

mescaline,

enhance

glutamatergic

neurotransmission in the prefrontal cortex by increasing the frequency of the excitatory
postsynaptic potentials (EPSPs) in the apical dendritic region of the layer V pyramidal
cells.91,139 As discussed earlier, malfunctioning NMDA receptors on the interneurons
(Figure 10) could lead to loss of GABAergic control of the dopaminergic influence on the
mesolimbic regions.68,91 An increase in the glutamatergic neurotransmission and a lack of
inhibition by GABA can perhaps explain the positive symptoms of schizophrenia.91 A
potential explanation for the negative symptoms and cognitive deficits is an overactivation
of GABA interneurons by a hyperactive glutamate signaling and the resulting
overinhibition of the dopaminergic pathway to the mesocortical region.68,91,131

Currently, the pharmacological treatment of schizophrenia entails one or more of the
atypical antipsychotics (Figure 1).12,23 However, since the DA and 5-HT hypotheses could
not completely explain the behavioral or the neuropathological changes occurring in
schizophrenia, glutamate receptors are now being explored as potential antipsychotic
targets.23,68 Additionally, a pharmacological agent targeting both the serotonergic and
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glutamatergic aspects of schizophrenia (a heteromer of 5-HT2A and mGlu2 receptors) could
be more efficacious in treating the disorder.9

C. THE 5-HT CLASS OF RECEPTORS:
5-HT receptors (5-HT1-5-HT7) can be divided into seven main classes that can further be
divided into several subclasses.80 With the exception of 5-HT3, which is a ligand-gated ion
channel, all other 5-HT receptors belong to the class A GPCR superfamily of
receptors.80,140 They consist of seven transmembrane-spanning helices and have an
extracellular N-terminus and an intracellular C-terminus.80 Listed below in Table 2 is the
current classification of 5-HT receptors into seven main classes and their respective
subclasses.80

Table 2. Classification of 5-HT receptors adapted from Glennon and Dukat.80
Populations and
Subpopulations

Second messenger
System

Currently
Accepted
Name

Comments

5-HT1
5-HT1A

AC (-)

5-HT1A

5-HT1B

AC (-)

5-HT1B

5-HT1Bβ

Cloned and pharmacologic
5-HT1A receptors
Rodent homolog of 5HT1B receptors
A mouse homolog of h5HT1B receptors
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5-HT1D

Sites identified in binding
studies using human and
calf brain homogenates
A cloned 5- HT1D
subpopulation

5-HT1Dα

AC (-)

h5-HT1D

Human counterpart of rat
5-HT1B

5-HT1Dβ

AC (-)

h5-HT1B

Sites identified in binding
studies using brain
homogenates and cloned
receptors

AC (-)

5-HT1E

5-HT1E

5-HT1Eα

5-HT1Eβ

Cloned h5-HT1E

AC (-)

5-ht1F

5-HT1F

Cloned mouse homolog of
5-HT1F receptors
Cloned h5-HT1F receptors

5-HT2
5-HT2

PI

5-HT2A

Originally
5-HT2

5-HT2F

PI

5-HT2B

5-HT2-like, found in rat
fundus
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known

as

5-HT1C

PI

5-HT2C

Originally known as
5-HT2C

5-HT3

Ion Channel

5-HT3

Ligand-gated ion channel

5-HT4

AC (+)

5-HT4

5-HT4S

Short form of
5-HT4 receptors

cloned

5-HT4L

Long form of cloned
5-HT4 receptors

5-HT5
5-HT5A

?

5-HT5A

Cloned mouse, rat and
h5-HT5 receptors

5-HT5B

?

5-HT5B

Cloned mouse and rat
5-HT5 receptors

5-HT6

AC (+)

5-HT6

Cloned rat and h5-HT
receptor

5-HT7

AC (+)

5-HT7

Cloned rat, guinea pig and
h5-HT7
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1. 5-HT2A RECEPTORS AND SOME LIGANDS TARGETING THEM:
5-HT2A receptors are a major target of atypical antipsychotics, antidepressants,
hallucinogens and other psychoactive drugs, as well as some antihypertensive drugs.77,140
They are GPCRs and are coupled to the Gα/q subunit of the heterotrimeric G-proteins
(Figure 12).141

Activation of 5-HT2A receptors leads to several downstream events such as the activation
of phospholipase C (PLC), catalyzing hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then releases
calcium ions (Ca2+) from the endoplasmic reticulum (ER) which then activates inwardly
rectifying chloride channels (Figure 12).80,140,141
Cl($
5(HT$
GIRK3$
Gαq$

DAG$

PLC$

DAG$

PIP2$
β$
γ$

Ca2+$

OTHER$EFFECTS$

IP3$

ER$

ER: Endoplasmic reticulum

Figure 12. The second messenger signal transduction pathway of 5-HT2A receptors.80,141
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Tools such as radioactively labeled ligands, in situ hybridization, RT-PCR and
immunocytochemistry have revealed the CNS presence of 5-HT2A receptors in the cerebral
cortex, basal forebrain, hippocampus, amygdala, hypothalamus, superior colliculus, latero
dorsal tegmental nucleus, spinal cord motor neurons, sympathetic and sensory neurons and
the peripheral presence in vascular, gastrointestinal smooth muscles, platelets and retina.141
Initially, 5-HT receptor binding sites were investigated using a number of radioactively
labeled ligands such as [3H]-5-HT, [3H]-LSD, and [3H]-spiperone.141 Spiperone (41) was
selective for 5-HT2A over 5-HT2C (about 1000 fold) however; it had high affinity for
dopamine D2 receptors (Figure 13).142 Ketanserin (42) was the first ligand to selectively
label 5-HT2A receptors (referred to as 5-HT2 receptors or S2 receptors back then) (Figure
13).143 It was devoid of activity at 5-HT1 receptors and had minimal affinity for dopamine
D2 receptors. It became a prototypic 5-HT2 antagonist with high binding affinity (Ki = 3.5
nM at 5-HT2A and Ki = 50 nM at 5-HT2C receptors in rat frontal cortex)143 and has
remained a radioligand of choice for investigations at 5-HT2 receptors for over two
decades.142–144
DOI is a 5-HT2A agonist (highly selective for 5-HT2 sites) and is a hallucinogen.145 Our
laboratory had previously reported that the R(-) stereoisomer is more active.145,146 Its
radiolabeled form, [125I]-R(-)-DOI is used to label 5-HT2A receptors that were traditionally
labeled with antagonists such as spiperone, ketanserin and partial agonists such as LSD.
[125I]-R(-)-DOI led to the labeling of the low density, high affinity sites for 5-HT2A
agonists.147
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Figure 13. Radioligands commonly used to label 5-HT2A receptor sites.142,146

5-HT2A receptors have been a subject of great interest since atypical antipsychotic agents
such as clozapine (2) and risperidone (3) were found to be dual serotonin-dopamine
antagonists (SDAs) and having a higher binding affinity for 5-HT2A receptors over
dopamine D2 receptors.8,30 In the late 1990s, it was observed that some atypical
antipsychotic agents could inhibit the constitutive activity of 5-HT2A receptors and
possessed inverse agonist activity.26

2. THE 5-HT2A-mGLU2 HETEROMER:
The 5-HT2A receptor specifically forms a heterodimer with the mGlu2 receptor.61 The two
receptors have been shown to co-localize in mouse cortical slices and neuronal primary
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cultures in autoradiographic studies (Figure 14) and interact to downregulate the Gα/q
signaling of 5-HT2A receptors and upregulate the Gi/o signaling of mGlu2 receptors.9,61

(A)

(B)

Figure 14. Overlay of 5-HT2A and mGlu2 receptors in mouse somatosensory cortex (A),
and mouse cortical primary culture (B).61

Clozapine (2) and risperidone (3) were found to crosstalk (downregulate the Gα/q signaling
of 5-HT2A receptors and upregulate the Gi/o signaling of mGlu2 receptors when the two
receptors are coexpressed) at the 5-HT2A-mGlu2 heterodimer and this target is currently
being explored with respect to the pathophysiology of schizophrenia and the mechanism of
action of certain hallucinogens.9,61
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CHAPTER III: SPECIFIC AIMS

The pharmacological and biochemical profile of risperidone (3) was extensively explored
in the mid-1980s – around the time it was realized that excessive DA might not be the only
contributing factor in schizophrenia.131,148 The serotonergic component of antipsychotic
activity was gaining increasing importance with the discovery that several 5-HT receptor
(specifically 5-HT2A, referred to as 5-HT2 sites then) antagonists (Figure 15) such as
spiperone (41) inhibited the pharmacological actions of the 5-HT receptor agonist
tryptamine (TRY) as well as apomorphine (APO)-induced stereotypy with potency being
directly related to binding affinity.149 Ligands having a ‘mixed’ or dual serotonindopamine antagonism (SDA) profile, such as risperidone (3) (ED50 = 0.028 mg/kg) and
pirenperone (43) (ED50 = 0.020 mg/kg) (Figure 15) dose-dependently attenuated the LSDcue in drug discrimination studies, and differed from the selective 5-HT2A antagonist
ritanserin (44) (ED50 = 11.6 mg/kg), which was not a very potent blocker of the LSD-cue,
and the classical D2 receptor antagonist haloperidol, which did not block the
LSD-cue.150–154
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Figure 15. Representative structures of 5-HT2A antagonists.155,156

Risperidone (3) is said to be a prototype of centrally active ligands having optimum
dopamine D2 receptor and 5-HT2A receptor binding affinity and antagonist activity.24,148,155
In fact, atypical antipsychotics have a greater affinity for 5-HT2A receptors, as compared to
D2 receptors and Meltzer had defined a ratio of D2/5-HT2A binding affinities, with a higher
value being conducive for atypical antipsychotic-like activity.25

The development of risperidone (Figure 16), stemmed from the need to integrate
antiapomorphine and anti-tryptamine activities in a single centrally active ligand with good
bioavailability.149,157
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Figure 16. The development of risperidone from butyrophenones.157

The development of risperidone began with two structurally related butyrophenones –
benperidol (also known as benzperidol) (45) and lenperone (46) having affinity for the
dopamine D2 receptor (Figure 16).157 Benperidol and lenperone had two aromatic groups
separated from the central nitrogen atom by 4 carbon atoms and their structures could be
considered as two ‘halves’ or ‘fragments’ around the central nitrogen atom (Figure
48

17).142,157 As both ligands bound to dopamine D2 receptors (Table 3), it was believed that
the

benzoyl

moiety

of

lenperone

had

pharmacophoric

similarities

with

the

benzimidazolone moiety of benperidol.157
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Figure 17. The ‘halves’ or ‘fragments’ of benperidol and lenperone.157

Structural combinations of the fragments of benperidol and lenperone were then
synthesized and evaluated for binding affinity and activity. Combining the two
benzimidazolone fragments led to domperidone (47), which had affinity for peripheral DA
receptors and activity only in the APO-induced emesis test in dogs suggesting peripheral
activity and limited or no central activity.157 A combination of benzimidazolone with the
benzoyl fragment led to declenperone (48) and milenperone (49), which were centrally
active dopamine D2 antagonists with weak 5-HT2A antagonist activity (Table 3).157

Further, several modifications to the benzimidazolone ring eventually led to the
quinazolinedione ring system, represented by ketanserin (42).144,157 This increased the
5-HT2A antagonist activity and imparted a 100-fold selectivity over D2 receptors.
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Ketanserin had high affinity and functional activity at 5-HT2A receptors and limited central
and peripheral D2 antagonist activity (Table 3).144,157,158

Replacement of the quinazolinedione ring with several different saturated and unsaturated
heterocyclic ring systems led to the development of pirenperone (43), a potent 5-HT2A and
D2 receptor antagonist, having ∼8-fold selectivity for 5-HT2A receptors over dopamine D2
receptors.157 However, it suffered from poor oral bioavailability. In a quest to develop
metabolically stable molecules, changes were made on the right side of pirenperone and its
analogs, giving rise to ritanserin (44), which had high selectivity for 5-HT2A receptors over
D2 receptors.155

Another approach to deter metabolism and increase bioavailability was based on the
isosteric replacement of the benzoyl fragment with a benzisoxazole ring, giving rise to
risperidone (3).148,157 Risperidone was centrally active and had excellent oral
bioavailability. It was a potent antagonist at both receptors with about 20-fold selectivity
for 5-HT2A (Ki = 0.16 nM) over D2 (Ki = 3.1 nM) and also had affinity for α1-adrenoceptors
and histamine H1 receptors in the nanomolar range.157,159 Risperidone seemed to combine
the favorable structural features of all its predecessors in terms of affinity and activity at D2
and 5-HT2A receptors.
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Table 3. Binding affinity and functional activity profile of risperidone and its predecessors
adapted from Megens et al.157
Receptor binding Ki (nM)

Activity against central 5-HT2A
and D2 receptors ED50 (mg/kg,
s.c.)

Agent

5-HT2A

D2

TRY (5-HT2A)

APO (D2)

Benperidol

6.60

0.35

0.29

0.0093

Lenperidol

Not tested

4.60

0.39

0.085

Declenperol

2.40

9.30

2.40

0.44

Milenperone

9.20

3.90

0.51

0.025

Domperidone

330

0.90
220

> 40
2.40

> 40

Ketanserin

2.10

> 40

Pirenperone

2.10

16.00

0.11

Ritanserin

1.20

23.00

0.26

Risperidone

0.16

3.10

0.13

0.15

Paliperidone

0.22

4.10

0.22

0.39

0.098
>160

*Radioligand binding studies were performed in rat frontal cortex homogenates with [3H]spiperone. TRY and APO-assays studied inhibition of bilateral clonic seizures and agitation
induced by TRY and APO, respectively.157

In order to compare its serotonergic and dopaminergic activity components, risperidone (3)
was explored for its in vitro and in vivo affinity and activity and was compared to
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ritanserin (44) (a centrally acting selective 5-HT2A antagonist) and haloperidol (9) (a
selective D2 antagonist).148,150

Similar to ritanserin, risperidone showed antagonist activity in all tests related to central
and peripheral 5-HT2A receptors, such as clonic seizures and tremors in rat forepaws
induced by TRY, mescaline- and 5-hydroxytryptophan (5-HTP)-induced twitches with
ED50 values of 0.014 mg/kg, 0.019 mg/kg and 0.016 mg/kg, respectively, and was more
potent than ritanserin.150

As regards activity against D2 receptors, risperidone antagonized central and peripheral
dopaminergic activities such as apomorphine-induced emesis in dogs, amphetamine- and
cocaine-induced agitation and stereotypies (Table 3).150,157 While haloperidol seemed to
have a narrow dose range of 1:3.5 for all effects including locomotion, risperidone had a
dose range of 1:10, excluding effects on locomotion, which were above this broad range.150

Risperidone was found to be 10 times more potent at central 5-HT2A receptors than at
central dopamine D2 receptors.160

That risperidone had an antipsychotic-like profile different from haloperidol and other
typical antipsychotics, was evident from the fact that it was a very potent LSD antagonist
(ED50 = 0.028 mg/kg) in drug discrimination studies.153 Haloperidol (selective D2
antagonist) does not affect the discriminative stimulus and ritanserin (selective 5-HT2A
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antagonist) is not a very potent blocker (ED50 = 11.6 mg/kg) of the discriminative
stimulus.150,152 In an open trial, risperidone (2-8 mg p.o. for 28 days) was effective in
improving the condition of schizophrenia patients resistant to typical antipsychotics and
having a major component of negative symptoms, without inducing EPS.161

It was believed that the 5-HT2A component of the activity could be responsible for the
effect of risperidone on negative symptoms of schizophrenia, as selective 5-HT2A
antagonists such as pipamperone and ritanserin had demonstrated antidepressant-like
properties and reduced catalepsy in rats.162 This hypothesis was further supported by
electrophysiological studies that showed that a marked antagonism of 5-HT2A receptors (as
shown by risperidone) could lead to a release of DA from the midbrain, which in turn
could lead to release of DA in the nucleus accumbens and prefrontal cortex, thus
circumventing the symptoms of lack of affect and concentration.8,160

Risperidone proved to be unique in its receptor occupancy profile when compared to
haloperidol (9) and clozapine (2) (another atypical antipsychotic). Apart from binding
primarily to 5-HT2A receptors (clozapine binds primarily to histamine H1 receptors and
haloperidol to D2 receptors), risperidone had a shallow occupancy curve at D2 receptors in
the striatum and mesolimbic regions – suggesting a gradual increase in the occupancy of
the receptor with increasing doses (Figure 18).159 Risperidone occupied 50% of 5-HT2A
and dopamine D2 receptors at a dose of 0.0075 and 2.5 mg/kg s.c., respectively. At a dose
at which 50% of D2 receptors are occupied, there is full occupancy of 5-HT2A sites, which
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as previously described, can be helpful against negative symptoms.8,160 Also, the gradual
occupation of D2 receptors suggests that at a lower dose and with partial occupation,
risperidone might be helpful against positive symptoms without inducing EPS.

(A)

(B)

Figure 18. The receptor occupancy profile of risperidone (ο), clozapine (☐) and
haloperidol (Δ) at 5-HT2A receptors (A), and dopamine D2 receptors (B).8

Physiologically, risperidone is metabolized by three major pathways in humans, rats and
dogs leading to active and inactive metabolites: alicyclic hydroxylation, oxidative Ndealkylation and cleavage of the benzisoxazole ring (Figure 19).163 The major active
metabolite is paliperidone (7), which is the product of hydroxylation at the 9-position.157 7Hydroxylated (7-OH) 50, dihydroxylated 51, benzisoxazole ring cleavage products 52 and
oxidative N-dealkylated 53 and 54 also form a small percentage of the metabolites.163 One
of the metabolites in dogs, which is also a putative metabolite in humans, is 55 and it is a
part of the current as well as past investigations by our laboratory.164
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Figure 19. Metabolism of risperidone adapted from Mannens et al.163

Although paliperidone and risperidone differ by a hydroxyl group, they possess similar
binding affinity for both 5-HT2A and D2 receptors (risperidone possesses a slightly higher
affinity for both receptors).45 Several groups have attempted to explore the possible
pharmacological and/or downstream signaling consequences of this structural difference
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and have found differences at the mitochondrial, neuronal firing and synaptic plasticity
level.45,165 However, since the hydroxyl group could contribute in terms of additional
interactions at the receptor and also change the physical and chemical properties, further
studies are needed to validate the exact role of the hydroxyl group and that is a part of the
current investigation.

Similar to several other GPCRs (e.g. α1A- and β2-adrenergic and 5-HT2C receptors), 5-HT2A
receptors possess constitutive activity and stimulate PIP2 hydrolysis in the absence of
agonist stimulation.166,167 This phenomenon was shown in 5-HT2A receptors by a single
amino acid mutation (C322K). Risperidone (and even paliperidone later on) was shown to
inhibit the constitutively activated PIP2 hydrolysis and to possess inverse agonist
activity.166

The inverse agonist activity of risperidone was evident by another approach. Similar to
clozapine (another atypical antipsychotic and inverse agonist at the 5-HT2A receptor),
risperidone crosstalks in the 5-HT2A-mGlu2 heteromer in such a way as to balance the GiGαq signaling and possessing a high balance index (BI) [BI = ΔGi - ΔGq].9 Through the
crosstalk, risperidone downregulates the unusually high Gαq signaling back to basal level
and maintains the balance between the Gi-Gq signaling, which is disrupted in
schizophrenia.9
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Risperidone possesses some structural features, which confer upon it a unique balance of
receptor affinity and functional activity, quite different from structurally related
predecessors.

The specific aims of the current investigation are:
1. Determination of the minimal structural features responsible for the antagonist
activity of risperidone/paliperidone at 5-HT2A receptors – Deconstruction of
risperidone/paliperidone
1a. Deconstruction of risperidone/paliperidone into smaller analogs and assessing their
functional activity and binding affinity
1b. Investigating the role of the hydroxyl group of paliperidone

Deconstruction will involve the systematic removal of specific functional groups of
risperidone to generate analogs lacking some features, which will be tested for functional
activity and binding affinity by electrophysiological assays and radioligand binding
studies, respectively.

2. Investigation of the structural differences between risperidone and ketanserin and
the role of the two halves of risperidone in its activity – Elaboration of risperidone
2a. Examination of structural hybrids of risperidone and ketanserin
2b. Investigation of the role of the right half of risperidone in its functional activity
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2c. Investigation of the role of the benzisoxazole ring in the functional activity and
binding affinity of risperidone
2d. Investigating the role of Arien’s hypothesis in the antagonist activity of risperidone

Elaboration will involve the substitution of the left and right halves of risperidone with the
left and right halves of ketanserin. The potential role of the right half of risperidone in
antagonist activity will be explored by making it as similar to 5-HT as possible. The
analogs will be tested for binding affinity and functional activity by radioligand binding
studies and electrophysiological assays, respectively.

3. Molecular modeling studies to understand the binding mode of risperidone and its
analogs at 5-HT2A receptors
Homology models of the 5-HT2A receptors will be constructed and the compounds will be
analyzed for their binding poses and interactions with amino acids at the receptors by
docking and scoring. The interactions will be validated by previous site-directed
mutagenesis data and quantified by performing Hydropathic INTeraction (HINT) studies.
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CHAPTER IV: APPROACH, RESULTS AND DISCUSSION

A. DECONSTRUCTION OF RISPERIDONE:
1. Approach:
The medicinal chemistry principles of ‘deconstruction-reconstruction-elaboration’ were
used to examine the structural features contributing to the antagonist activity of risperidone
and paliperidone at 5-HT2A receptors.168
This approach basically helps to understand which functional groups making up the
structure of a compound contribute to its activity and binding affinity. The study begins
with deconstruction, which involves the systematic removal of functional groups of the
parent compound, to generate analogs lacking some features. The smaller analogs lacking
certain features of the parent compound are then tested for functional activity and/or
binding affinity. The change in the activity and/or affinity compared to the parent
compound reflects the role of the functional group that is removed.168 For example, if
removal of a carbonyl group leads to a 20-fold decrease in affinity, this indicates that the
polar interactions that the carbonyl group is capable of making might be important for
binding affinity. Similarly, if removal of a phenyl group leads to a negligible increase or
decrease in activity, this suggests that the phenyl group does not contribute significantly to
activity, and can be removed or replaced.
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Deconstruction helps to simplify the structure to the minimum structural features
responsible for activity and affinity. This is helpful in determining a pharmacophore for
that particular activity.

The structure of risperidone/paliperidone was systematically deconstructed and its
structural features were explored as shown in Figure 20.
N O
O

N
R

F

N

N
CH3

R = H; Risperidone (3)
R = OH; Paliperidone (7)

Figure 20. Approach to the deconstruction of risperidone/paliperidone. Circled regions
represent structural features that were excised.

Risperidone can be divided into two halves: 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]
isoxazole (right half) and 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
(left half) connected by an ethyl linker. The halves were explored further to determine their
respective contribution towards activity and affinity (Figure 21).

Our laboratory had in the past explored the structure-activity relationships (SAR) of
ketanserin (42) by deconstruction (tested on the frontal cortical homogenates of male
Sprague-Dawley rats using [3H]-ketanserin]).143 We have used a similar approach in our
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study of risperidone (Figure 20). Figure 21 shows all the deconstructed analogs of
risperidone included in the present study.
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Figure 21. The halves of risperidone/paliperidone and the deconstructed analogs.

As a starting point for the current investigation, the 6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one ring system comprising the left half of risperidone was opened to give
the tertiary amide, a compound retaining the carbonyl group, 56. The carbonyl group of 56
was removed (reduced) to afford 57. These analogs retain part of the hydrophobicity of the
6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system. Herndon et al.143 had
previously reported similar modifications on the structure of ketanserin, and the analogs
retained binding affinity for the receptor (Figure 22).
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Figure 22. A comparison of the deconstruction of ketanserin and risperidone. Binding data
are provided for ketanserin and its deconstructed analogs at 5-HT2A receptors.143

Similar deconstruction studies were also conducted with paliperidone (i.e., 59). A
comparison of the result of the two series will be informative regarding the role of the
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hydroxyl group – whether it plays a role in binding affinity and/or activity, or whether it is
merely tolerated.

Thereafter, the left portion of risperidone was removed to give the N-methyl analog 58 that
retains a part of the alkyl bridge connecting the two halves of risperidone in the form of a
methyl group. This methyl group was then removed to give analog 55, which was reported
previously by our laboratory.164 Herndon et al.143 had similarly deconstructed and tested
the right half of ketanserin (42) (i.e., 62) and reported that there is a dramatic loss of
binding affinity (∼120 fold) when compared to ketanserin (Figure 22).143 Removal of the
methyl group of 63 to afford the desmethyl analog 62 resulted in a ∼3-fold lower binding
affinity over the N-methyl analog 63. (Figure 22).143

Based on the preliminary results of the functional activity of 55, the precise role of the
benzisoxazole ring system and its substituents was probed where the benzisoxazole ring
was kept constant and the substituents were varied (Figure 21). Herndon et al.143 had
reported that the desfluoro analog (i.e., 66) of 62 (Figure 22) displayed ∼8-fold decreased
affinity and more than 900-fold decreased affinity compared to ketanserin (42), suggesting
a role of the fluoro group in binding.143 Evaluation of desfluoro analogs 60 and 61 should
reveal the importance of the fluoro group in the binding affinity of risperidone and its
deconstructed analogs.
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2. Results:
a. Chemistry:
The synthesis of the deconstructed analogs of risperidone was carried out in collaboration
with others in our laboratory. Rakesh Vekariya initially synthesized the compound without
the carbonyl group 57 and the synthesis is outlined in Scheme 1. Compounds 56 and 57
were re-synthesized through a common intermediate 67, which was synthesized by
reacting freshly distilled piperidine (68) with the acid chloride 4-chlorobutyryl chloride
(Scheme 1).169 The synthesis of compound 56 was initially attempted by heating at reflux,
however, the reaction did not go to completion and the yields were poor. Subsequently, a
Finkelstein reaction was tried under pressure in a screw-cap vial that drove the reaction to
completion and the yield was increased from 1% to 10%. The free base of 56 when
subjected to reduction with BH3-THF, followed by acidic hydrolysis, afforded 57 (Scheme
1).
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Scheme 1. Synthesis of compounds 56 and 57a
O
NH

a

Cl

N

b
68

67

N O
O

F

N

N

56
c

N

N

N O
F

57
a

Reagent: (a) 4-Chlorobutyryl chloride, Et3N, CH2Cl2, room temperature, 75 h; (b) 6fluoro-3-(piperidin-4-yl)benz[d]isoxazole, K2CO3, KI, MeCN, screw-cap vial, 88 °C, 16 h;
(c) (1) BH3-THF, THF, reflux, 2 h; (2) 6N HCl, reflux, 1 h.

The paliperidone counterpart 59 was synthesized similarly. However, the starting material,
(±)3-hydroxypiperidine (69), had a free hydroxyl group which could potentially interfere
with the subsequent reactions that would be conducted at the amine group. Hence, attempts
were made to protect this group using a trimethylsilyl ether (TMS), which was
unsuccessful with starting material being recovered. Thereafter, the benzyl ether of (±)3hydroxypiperidine (71) was synthesized and the ensuing reactions gave good yields;
however, subsequent efforts to remove the benzyl protecting group proved fruitless.
Debenzylations with hydrogenolysis at atmospheric pressure and under pressure with
various reaction conditions were attempted (Scheme 2).
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Scheme 2. Initial attempts to synthesize compound 59a
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Reagent: (a) Benzylchloride, tetraethylammonium bromide, CH2Cl2, room temperature;
(b) TMSCl, imidazole, DMF, room temperature, 20 h; (c) 4-chlorobutyryl chloride, Et3N,
CH2Cl2, room temperature, 75 h; (d) 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole, K2CO3,
KI, MeCN, screw-cap vial, 88 °C, 16 h; (e) HCl/EtOH, EtOH, Pd/C (5%), hydrogen
balloon; (f) HCl/EtOH, EtOH, Pd/C (10%), hydrogen balloon; (g) HCl/EtOH, EtOH, Pd/C
(10%), Parr hydrogenator, 15 psi; (h) HCl/EtOH, EtOH, Pd/C (10%), Parr hydrogenator,
55 psi.
A literature review provided information about the potential role of amines (a specific case
of a tertiary amine was reported) in hindering O-debenzylation by hydrogenolysis.170 Since
our compound also contained a tertiary amine, it was speculated that the amine might be
hampering the last step of O-debenzylation.

Eventually, the reaction was attempted without protecting the hydroxyl group of (±)3hydroxypiperidine (69) and, although the yields were moderate (∼30%), the reactions
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proceeded to finally yield 59. Compound 59 was synthesized through the intermediate 74,
(Scheme 3) and was obtained as an oxalate salt because its hydrochloride salt was
hygroscopic and difficult to isolate.

Scheme 3. Synthesis of compound 59a
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Reagent: (a) 4-Chlorobutyryl chloride, Et3N, CH2Cl2, room temperature, 75 h; (b) (1) 6fluoro-3-(piperidin-4-yl)benzo[d]isoxazole, K2CO3, KI, MeCN, screw-cap vial, 88 °C, 16
h; (2) oxalic acid, MeOH, Et2O.
The synthesis of compound 55 was reported by Strupczewski et al.,171 and was replicated
as outlined in Scheme 4. The amino group of isonipecotic acid (75) was protected by
formylation. This was followed by conversion to N-formylisonipecotic acid chloride (77),
which was generated in situ and was monitored by IR spectroscopy to denote the loss of
the broad peak of the –OH group of the carboxylic acid of isonipecotic acid (75) at 3200
cm-1. The acid chloride was subjected to acylation by Friedel-Crafts acylation reaction with
1,3-difluorobenzene to afford 78. This reaction was limited by the condition of AlCl3,
which was used in the same equivalence as the starting materials. The reaction was highly
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sensitive to moisture, and freshly sublimed AlCl3 was used for this step. The oxime 79 was
synthesized for the intramolecular displacement of the 2-fluoro moiety to afford
benzisoxazole 80. TLC suggested formation of both E and Z isomers, of which only the Z
isomer is believed to participate in the cyclization reaction. The formamide group was
removed by acidic hydrolysis (Scheme 4). Compound 58 was synthesized by Nmethylation of 55 using a Eschweiler-Clarke reaction.143 The subsequent

commercial

availability of 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole (55) facilitated the preparation
of additional product.
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Scheme 4. Synthesis of compounds 55 and 58a
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Reagent: (a) (1) HCOOH, Ac2O, 65 °C, 1 h; (2) room temperature, 16 h; (3) vacuum
distillation; (b) SOCl2, DMF, room temperature, 6 h; (c) 1,3-difluorobenzene, AlCl3,
ClCH2CH2Cl, reflux, 45 h; (d) hydroxylamine hydrochloride, NaOH/H2O, EtOH, reflux,
96 h; (e) NaH (toluene washed), DMF, room temperature, 48 h; (f) (1) conc. HCl, EtOH,
reflux, 3 h; (g) (1) HCOOH, HCHO, EtOH, reflux, 10 h; (2) HCl/Et2O.
The syntheses of compounds 60 and 61 followed the procedure reported by Strupczewski
et al.171 and are outlined in Scheme 5. Due to the unavailability of a commercial Grignard
reagent, 4-chloro-N-methylpiperidine (81) was converted to a Grignard reagent in situ and
reacted with the cyano compound 2-fluorobenzonitrile to give the acylated product 82.
This compound was cyclized by a one-pot conversion of the acylated product oxime and,
which by intramolecular displacement of fluorine, afforded 61. The N-methyl group was
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removed by converting it to a phenyl carbamate 83, followed by basic hydrolysis to yield
60 (Scheme 5).
Scheme 5. Synthesis of compounds 60 and 61a
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Reagent: (a) (1) 4-Chloro-N-methylpiperidine, THF, Mg, bromoethane, reflux, 1 h; (2)
room temperature, 2-fluorobenzonitrile, reflux, 3 h; (3) room temperature, 36 h; (4) NH4Cl,
50 °C, 2 h; (5) HCl/Et2O; (b) (1) KOH (85%), hydroxylamine hydrochloride,
ethoxyethanol, reflux, 6 h; (2) HCl/Et2O; (c) (1) NaOH, toluene, phenyl chloroformate,
reflux, 24 h; (2) petroleum ether; (d) KOH (85%), EtOH, reflux, 48 h; (2) HCl/Et2O.

b. Functional activity studies:
The functional activity studies of risperidone (3) and compounds 55-58 were performed in
Dr. Logothetis’ laboratory by Jason Younkin, Amr Ellaithy, Dr. Lia Baki and Sneha Shah,
and two biological assay systems were used: calcium imaging by an epifluorescence assay
using the Ca2+ sensitive dye Fura2AM in HEK293 cells stably expressing 5-HT2A
receptors, and the two-electrode voltage-clamp (TEVC) electrophysiological assay in a
Xenopus laevis oocyte heterologous expression system.172,173 Risperidone (3) and
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preliminary

studies

with

paliperidone

(7)

were

carried

out

in

the

TEVC

electrophysiological assay system.

The calcium imaging assay reflects the amount of calcium released from the endoplasmic
reticulum (Figure 12) on activation of IP3 receptors on the ER by IP3 when the 5-HT2A
receptor is stimulated. The potentiometric dye Fura2AM is sensitive to calcium and
chelates the released calcium and fluoresces at two wavelengths: 340 nM and 380 nM. A
ratio of the fluorescence at 340/380 nM is an indication of the concentration of calcium
released. At a concentration of 100 µM for compounds 55, 57 and 58 and 32 mM for
compound 56, the compounds by themselves generated no calcium signal (Figure 23).

71

A

100 µM

B

Wash 1 µM 5-HT Wash
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Figure 23. Compounds 55 (A), 56 (B), 57 (C), and 58 (D) did not generate the calcium
signal indicating the intracellular release of calcium (figures provided by Dr. Lia Baki).

As seen from Figure 23, the carbonyl compound 56 was not only difficult to ‘wash-off’
from the receptor but also inhibited the agonist activity of 5-HT. Compounds 55, 57 and
58, on the other hand could be ‘washed off’ so that 5-HT could exert its full agonist
activity at the receptor. However, when compounds 55-58 were applied in the presence of
5-HT, the compounds dose-dependently inhibited the activity of 1 µM 5-HT. Risperidone
was also included in this study. A typical dose-response curve (Figure 24) for the
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compounds was generated and the half maximal inhibitory constants (IC50 values) for the
compounds were calculated (Table 4).
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IC50 = 17930 nM

% of response

IC50 = 5761 nM

Risperidone, µM
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55, µM

D
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IC50 = 53490 nM

57, µM

56, µM

E

% of response
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58, µM

Figure 24. Dose-response curves for risperidone and compounds 55-58 by the calcium
imaging assay. Results are from a single experiment (figures provided by Dr. Lia Baki).
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The TEVC assay measures the inhibition of current from the inwardly-rectifying potassium
channel GIRK4* associated with the 5-HT2A receptor (Figure 25).172 Here, the K+ channel
functions as a “reporter” of the ligand-mediated Gαq activity. In the assay, the heterologous
oocyte system co-expressing the 5-HT2A receptor and the GIRK4* channel is perfused with
a solution of high concentration of K+ (HK), which sets a baseline current (sensitive to
Ba2+ ions). On stimulation of the receptor by the ligand, the Gαq subunit activates PLC
leading to the hydrolysis of PIP2 and release of IP3 and DAG. The activity of GIRK4* is
PIP2-dependent, and a decrease in PIP2 concentration (due to its hydrolysis) leads to
current inhibition through GIRK4*. The IP3-mediated release of calcium from the ER leads
to activation of chloride channels, (which is indicated by a spike at the onset of the
inhibitory current due to 5-HT) and phosphorylation of GIRK4* (Figure 25). The
phosphorylation of GIRK4*, also inhibits the potassium current, which is measured and
gives an indication of Gαq-mediated activity of the compound under study.174

The GTP-bound Gαq subunit is then acted upon by RGS2, which is a GTPase-activating
protein, converting GTP to GDP, and leading to the reassociation of Gαq subunit with the
βγ subunit, thereby stopping the current inhibition due to the ligand.174
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GIRK4* + 5-HT

RGS2: Regulator of G-protein
signaling 2

Figure 25. A schematic representation of the measurement of Gαq-mediated activity at
5-HT2A receptors by the TEVC assay.172

The TEVC assay is ∼10-fold more sensitive than the calcium imaging epifluorescence
assay. Preliminary studies with risperidone indicated an IC50 value of 57 nM and in the
presence of 5-HT, it brought the agonist activity of 5-HT (the normalized Gαq activity
considered as 100%) down to ∼20%. Compounds 55-58 inhibited the 5-HT-mediated Gαq
activity with IC50 values of 2800 nM, 199.7 nM, 16.8 nM and 101 nM, respectively
(Figure 26).
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E
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Figure 26. The dose-response curves for inhibitory activity exhibited by risperidone (A),
compounds 55 (B), 56 (C), 57 (D), and 58 (E) (figures provided by Jason Younkin).
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In the preliminary data, at a concentration of 10 µM, compounds 55-58 demonstrated Gαq
activity by themselves (Figure 27) with about 25% (55), 45% (56), 70% (57) and 30% (58)
of the activity of 5-HT (100% Gαq activity). However, at a concentration of 50 µM the
compound lacking the carbonyl group, 57, showed an agonist activity of ∼150% (Figure
27B).
A

B

55

58

56

57

57

µM

Figure 27. The positive efficacy of compounds 55-58 (A), and the potential ‘superagonist’
activity of compound 57 (B) (figures provided by Jason Younkin).

To ascertain whether the activity exhibited by the compounds is solely G-protein coupled
or due to independent activity at the GIRK4* channel, they were tested in an assay system
expressing the channel alone. Compound 57 showed strong agonist activity at the channel.
These studies have been continued and additional data generated (see Appendix A).

When the 5-HT2A receptor is activated by 5-HT, the release of calcium from the ER leads
to an increase in the intracellular positive ion concentration. This produces an initial
inward spike in the electrophysiological tracing after the application of the concentration of
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5-HT under study (Figure 28). The sharp inward spike then continues upwards to show
inhibition of the GIRK4* channel current, which is measured by the assay. The
intracellular calcium release simultaneously activates chloride channels (inward),
producing a strong outward current (reflected as an outward spike in the
electrophysiological tracing). This outward chloride spike was not observed with
compounds 55-58 (data shown for 58 in Figure 28). Also, the compounds produced a
rather broad inward peak instead of the sharp spike shown by the application of 1 µM of
5-HT. This is similar to the lack of calcium signal observed with the calcium imaging
assay.
A

B

N O

H 3C

F

N

58

5-HT
58

Figure 28. The outward current due to the inward movement of chloride ions and the
inward current due to the intracellular release of calcium ions after application of 5-HT
(A), and the lack of inward and outward current after the application of the compounds,
represented by the N-methyl compound 58 (figures provided by Jason Younkin).

It was interesting to note that in the preliminary studies with paliperidone (7), a
concentration of 5 µM in the absence of 5-HT, led to a reversal of basal current, which is
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reminiscent of inverse agonist activity. This study with paliperidone is currently under
further investigation.

As discussed earlier, risperidone, similar to clozapine, crosstalks in the 5-HT2A-mGlu2
heteromer and this is an indication of their inverse agonist activity. The crosstalk is evident
from a decrease in 5-HT induced Gαq activity of the 5-HT2A portion, and a simultaneous
increase in glutamate-induced Gi activity of the mGlu2 portion of the heteromer.9
Compounds 55-58 were tested in the heteromer expressed in the Xenopus laevis oocyte
heterologous expression system, wherein the 5-HT2A-mediated Gαq activity was measured
by the inhibition of the GIRK3 channel and the glutamate-mediated Gi activity was
measured by the activation of the GIRK4* channel. Compound 55 was able to crosstalk
across the heteromer system (Figure 29), while compounds 56-58 were incapable of
exerting this effect. This crosstalk effect is currently under further investigation.
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A

B

55

55

Figure 29. The crosstalk in the 5-HT2A-mGlu2 heteromer system exhibited by compound
55 (figures provided by Jason Younkin).

c. Radioligand binding studies:
The radioligand binding assay was conducted in Dr. Javier González-Maeso’s laboratory
by Dr. José L. Moreno. These studies were performed in HEK293 cells expressing 5-HT2A
receptors with [3H]-ketanserin (Ki = 2 nM) as the radioligand. Non-specific binding was
determined in the presence of 10 µM methysergide and competition curves were generated
and analyzed by nonlinear regression to derive the dissociation constants (Ki values)
(Figure 30).
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A

Ki = 5.22 ± 1.40 nM

B

C

Compound 55

Compound 56
Ki = 42.97 ± 16.33 nM

Ki = 75.75 ± 30.77 nM

D

E
Compound 57

Compound 58
Ki = 18.77 ± 11.12 nM

Ki = 35.20 ± 7.32 nM

Figure 30. Radioligand binding affinity at 5-HT2A receptors expressed in HEK293 cells of
risperidone (A), compounds 55-58 (B), (C), (D), (E), respectively (figures provided by Dr.
José L. Moreno).
Binding affinities of risperidone and the deconstructed analogs 55-58 were determined in
this assay system and resulted in Ki values of 5.22 ± 1.40 and 75.75 ± 30.77, 42.97 ±
16.33, 35.20 ± 7.32 and 18.77 ± 11.12 nM, respectively (Table 4).
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Table 4. Results from the functional and binding assays.
Calcium
imaging
assay
(IC50, nM)
N O

5,761

O

F

N

N
N

TEVC assay;
percent
reduction of
5-HT-induced
Gαq activity*

Radioligand
binding assay,
Ki ± SEM
values (nM)

∼20%
IC50 = 57 nM

5.22 ± 1.40

CH3

Risperidone (3)
N O

H

17,930

IC50

∼25%
= 2800 nM

75.75 ± 30.77

F

N

55
N O
O

F

N

N

15,500

∼45%
= 199.7 nM

42.97 ± 16.33

53,490

∼70%
IC50 = 16.8 nM

35.20 ± 7.32

10,720

∼30%
IC50 = 101 nM

18.77 ± 11.12

IC50

56
N O
F

N

N

57
N O

H 3C

F

N

58
*Preliminary data.
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3. Discussion:
The calcium imaging epifluorescence assay showed that compounds 55-58 are capable of
inhibiting the activity of 5-HT at the receptor. As the compounds do not produce any
calcium signal (which is a reflection of activity in this assay) by themselves, it suggests
antagonist activity.

The TEVC electrophysiological assay system, however, owing to its sensitivity, indicated
a positive efficacy of compounds 55-58 that at the tested concentration of 10 µM, was
lower than the activity produced by 5-HT at 1 µM. Compounds 55, 56 and 58 inhibited the
activity of 5-HT, essentially bringing it down to their respective efficacies. This is in
agreement with the definition of a partial agonist, which is a ligand having positive
efficacy lower than that of a full agonist, and antagonizes the activity of the full agonist by
competing for the orthosteric site (the primary binding site of the endogenous ligand).175

The positive efficacy of compound 57 is considerably higher than the other compounds
and at a concentration of 10 µM, the activity of 57 when tested by itself, was close to that
of 5-HT (1µM). At a concentration of 10 µM, 57 inhibits the action of 5-HT to 70% (its
own efficacy; Figure 27) fitting the profile of a high potency partial agonist. However,
when compound 57 was tested at a concentration of 50 µM, it produced an activity of
∼150% (Figure 27), suggesting enhanced agonist activity or potential ago-allosteric
activity (see Appendix A).
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To examine this in greater detail, additional studies were performed. The agonist action of
compound 57 could be due, in part, to its effect on the GIRK4* channel. Indeed, when
examined in cells lacking 5-HT2A receptors, 57 still produced an “agonist” effect (see
Appendix A).

The action of 57 could also involve an allosteric effect. Hence, it was important to
determine whether or not 57 binds at the 5-HT2A orthosteric site. Radioligand binding
studies revealed that 57 binds at the orthosteric site with high affinity (Ki = 35 nM)
suggesting that it exerts at least part of its activity through the orthosteric binding site of
the receptor.

The fact that the compound retaining the carbonyl group 56 and without the carbonyl
group, 57, show comparable binding affinity, suggests that the carbonyl group might not
be essential for binding at the 5-HT2A receptors.

The high binding affinity of the N-methyl analog 58 (only ∼3 fold lower than risperidone)
suggests

that

the

6-fluoro-3-(1-methylpiperidin-4-yl)benz[d]isoxazole

portion

of

risperidone is sufficient to maintain high binding affinity at the receptor. Similar to their
ketanserin counterparts, the N-methyl analog 58 and the desmethyl analog 55 differ by ∼4fold in their binding affinity, suggesting additional interactions by the N-methyl group at
the receptor.
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The functional data shows that the analogs lacking certain features of risperidone have
positive efficacy. As the structure of risperidone is deconstructed, the analogs 55-58 have
some positive efficacy and reflect partial agonist activity (or potential superagonist activity
in the case of 57). However, when compared to the activity of risperidone (3), which could
be due to noise and other factors, and which cannot be eliminated or accounted for at this
moment, compounds 55-58 could actually be behaving as neutral antagonists (supported
by the lack of the Ca2+ signal in both functional assays). This would be in agreement with
the studies carried out by our laboratory in the past, reported by Iwamura et al. in which 55
showed antagonist activity.164

The TEVC functional assay system has shown that the smaller deconstructed analogs of
risperidone, compounds 55 and 58 have a comparable inhibitory activity at 5-HT2A
receptors (Table 4). The radioligand binding assay has shown that the N-methyl compound
58 is comparable in affinity to risperidone. These results suggest that the right half of
risperidone, [(6-fluoro-(3-piperidinyl)benz[d]isoxazole] is important for its activity and/or
affinity.
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B. ELABORATION OF RISPERIDONE:
1. Approach:
The ‘elaboration’ approach of the medicinal chemistry principle of deconstructionreconstruction-elaboration’ was utilized to determine the role of the two ‘halves’ of
risperidone in imparting it with it’s inhibitory activity.

Elaboration involves replacing part of the molecule (which was thought to impart a
particular effect) with new substituents. In the current investigation, the right and the left
half of risperidone was replaced one at a time to investigate the role of that particular half
in its activity at the receptor. Ketanserin (42) is a prototypical antagonist at the 5-HT2A
receptor.144,158 Structurally, ketanserin can also be divided into two halves (Figure 31). In
fact, the right half of ketanserin, 4-(4-fluorobenzoyl)piperidine [bioisoteric with the right
half of risperidone – 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole] is known to possess
5-HT2A receptor antagonist activity.176 Our laboratory had reported in the past that the 6fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole portion of risperidone (i.e., compound 55)
possesses this antagonist activity.164
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Risperidone (3)
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Figure 31. A comparison of the left and the right ‘halves’ of ketanserin and risperidone.

The present investigation aimed not only to determine what structural features of
risperidone are responsible for its functional activity, but also what makes it different from
ketanserin, which is structurally similar. Ketanserin and risperidone possess striking
structural similarities (the right halves) and some structural differences (the left halves).
We replaced the left and the right halves of risperidone and ketanserin and created two
hybrid compounds 84 and 85 (Figure 32). The binding affinity and the functional activity
of these structural hybrids should be informative about the effect that the structures of
risperidone and ketanserin have on their functional activity and binding affinity.

The right hand portion of ketanserin (i.e., 63) binds with >35-fold lower affinity than its
parent143 (Figure 22) whereas its benzisoxazole counterpart (i.e., 58) binds only with 3-fold
lower affinity than risperidone (Table 4). This suggests that the right half of risperidone
contributes more towards binding affinity than the right half of ketanserin.
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Figure 32. The structures of risperidone (3), ketanserin (42) and hybrids 84 and 85.

If compound 84 loses inhibitory activity, it will tell us that the right half of risperidone is
indeed playing a role in the activity. Similarly, if compound 85 is inactive, this will mean
that the left half of risperidone contributes and is important for activity or the left half of
ketanserin does not contribute to the antagonist activity.

As reported previously by Iwamura et al.,164 the structure of the deconstructed analog of
risperidone, compound 55, is similar to that of structurally rigid tryptamines such as
RU 28253 (86) and RU 24969 (87) (Figure 33) of the tetrahydropyridylindole class of
compounds, which are potent 5-HT1 and 5-HT2 receptor agonists.164,177 Yet, Iwamura et
al.164 reported 55 to be a potent 5-HT2A receptor antagonist. In the present investigation
analogs 88 and 89, which are structurally related to RU 28253 (86) and RU 24969 (87) but
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still have the 6-fluoro group reminiscent of 55 (Figure 33), were synthesized to examine
their binding affinity and functional activity at 5-HT2A receptors. The results should reveal
the role of the benzisoxazole ring in maintaining binding affinity and activity at the 5-HT2A
receptor. As discussed earlier, the role of the ring substituents (fluoro group) of compound
55 was probed by synthesizing analogs lacking the fluoro group (i.e., 60 and 61).
Similarly, in the present study, the role of the substituents was probed further by replacing
the 6-fluoro group with a 5-methoxy group (i.e. 90). Compound 90 is similar to RU 28253
(86) and RU 24969 (87), which are known to be agonists at 5-HT receptors. If compound
90 is an antagonist, it would suggest that the benzisoxazole ring system might play a role
in converting an agonist (RU 24969) to an antagonist.
NH

NH

HN
H

OCH3

N

RU 24969 (87)

RU 28253 (86)

NH

NH

H

N

OCH3

F

H

88

N

F

89

N O

H

N

90

OCH3

Figure 33. Comparison of the benzisoxazole ring with tetrahydropyridylindole ring.164,177
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We replaced the right half of risperidone with one of the constrained tryptamines from our
study to give compound 91 (Figure 34). The purpose of this replacement is dual. First, we
will be investigating the role of the right half of risperidone by replacing it with another
group. Second, by replacing the benzisoxazole ring with an indole ring, we are making the
right half of risperidone more like 5-HT and other agonists at 5-HT receptors. If compound
91 retains antagonist activity it will support the Ariens hypothesis of conversion of
agonists to antagonists on addition of bulky substituents on amines. However, if 91 does
not exhibit antagonist activity, it could mean that either the left half of risperidone is not
contributing to its antagonist activity, or the right half of risperidone is important for the
activity.
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92
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Figure 34. Elaboration of risperidone with constrained tryptamine analogs.
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2. Results:
a. Chemistry
The synthesis of the elaborated analogs of risperidone was carried out in collaboration with
Urjita Shah from our laboratory, who synthesized compound 84, the synthesis of which is
outlined in Scheme 6.

Compound 84 was synthesized by a Finkelstein reaction between the heterocyclic alkyl
chloride 92 with 4-fluorobenzoylpiperidine hydrochloride in the presence of 2 equivalents
of K2CO3, because the amine is present as its hydrochloride salt, and KI as the catalyst.
The solvent, acetonitrile (MeCN), was utilized because with N,N-dimethylformamide
(DMF), the yields were poor. Also, the literature suggests that for reactions with
compound 92, solvents such as MeCN, i-PrOH and isobutanol work better than DMF.178
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Scheme 6. Synthesis of compound 84a
O
O

O
Cl

N
N

a

N

N

CH3

N

92

CH3

F

x 2HCl

84

a

Reagent: (a) 4-(4-fluorobenzoyl)piperidine hydrochloride, K2CO3, KI, MeCN, reflux,
16 h.
Multiple synthetic routes were attempted for the synthesis of compound 85, and with
different reaction conditions for a particular synthetic route (Scheme 7). The ketanserin-left
half counterpart of the heterocyclic alkyl halide 93 was initially reacted with N,Ndiisopropylethylamine (DIEA) or Hünig’s base in the presence of MeCN. The reaction did
not go to completion and neither the product, nor the starting material, could be isolated.
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Scheme 7. Initial attempts to synthesize compound 85a

a
N O

b

O
N
N
H

93

O

Cl
O

N

N

c
N
H

d

F

O

85

a

Reagent: (a) (1) 6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole, N,N-diisopropylethylamine
(DIEA), MeCN, room temperature, 23 h (2) 50 °C, 2h (3) reflux, 18 h; (b) 6-fluoro-3(piperidin-4-yl)benz[d]isoxazole, K2CO3, KI, DMF, reflux, 18 h; (c) 6-fluoro-3-(piperidin4-yl)benz[d]isoxazole,
K2CO3, KI, MeCN, 16 h; (d) 6-fluoro-3-(piperidin-4yl)benz[d]isoxazole, screw-cap vial, 88 °C, 16 h.

Next, based on the procedure for similar analogs reported by our laboratory in the past,143
a Finkelstein reaction was attempted, initially in the presence of DMF, which had a
tendency of giving multiple products from which the desired product was difficult to
isolate. Then MeCN was used as a solvent, however, it produced the same results as with
DMF. Another method was reported by Herndon et al.,143 which involved heating in a
screw-cap vial (sealed tube) in the presence of toluene. However, since no base was added,
the reaction did not go to completion.

Model reactions were conducted for the structurally similar compound 94, the starting
materials for which were more economical. A series of similar reactions outlined in
Scheme 7 were attempted for the synthesis of 94, which brought us to the conclusion that
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perhaps it was the synthetic routes and not the technique that was the undoing. Compound
94 was synthesized by yet another general procedure reported by Herndon et al.143 and
outlined in Scheme 8, which successfully resulted in compound 94. The reaction seemed to
work better with the tricyclic compound 95.179 Nucleophilic attack of the amine seemed to
occur best on the oxazoloquinazoline 95 with a minimum amount of solvent and when
done neat.

Thereafter, compound 85 was synthesized under high-pressure in a screw-cap vial (Scheme
8), which gave better yields. It was difficult to dissolve the free base of 85 in an
appropriate solvent for the preparation of its hydrochloride salt. A number of solvents such
as EtOH, MeOH, MeCN, CHCl3, CH2Cl2 and ethyl acetate (EtOAc) were attempted.
Finally, the free base was treated directly with conc. HCl to form the hydrochloride salt.
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Scheme 8. Synthesis of compounds 85 and 94a
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c
N
H

F

N

N
O

x HCl
85

a

Reagent: (a) K2CO3, acetone, reflux, 2 h; (b) piperidine, screw-cap vial, 98 °C, 4 h; (c) 6fluoro-3-(piperidin-4-yl)benz[d]isoxazole, toluene, screw-cap vial, 100 °C, 44 h.

Compounds 88 and 89 were synthesized from 6-fluoroindole (96) and compound 89 was
synthesized from 88 by reduction of the double bond by hydrogenation with Pd/C (10%)
under pressure and was submitted as a free base (Scheme 9). Compound 91 was
synthesized from compounds 89 and 92, and is outlined in Scheme 9. After the
optimization of the solvent, MeCN, for the Finkelstein reaction for compound 84,
compound 91 was also synthesized by refluxing in MeCN. The yield, 9%, as for other
Finkelstein reactions in this study, was low.
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Scheme 9. Synthesis of compounds 88, 89 and 91a
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Reagent: (a) 4-piperidone monohydrate hydrochloride, KOH, MeOH, reflux, 5 h; (b) (1)
HCl/EtOH, MeOH, Pd/C (10%), Parr hydrogenator, 43 psi; (2) NaOH; (c) (1) compound
92, MeCN, reflux, 45 h; (2) HCl/Et2O.
A synthetic route for compound 90 has been reported171 and it was synthesized in a manner
similar to that of 55, with the exception that the amino group of isonipecotic acid (75) was
protected by converting it to the acetamide 97 (Scheme 10). Demethylation of a methoxy
group in the Friedel-Crafts product 99 was due to excessive AlCl3 and dichloroethane
(ClCH2CH2Cl). The oxime was converted to its acetate salt 100 and then reacted further
with NaH to give the cyclized product 101. It has been suggested that the phenolic
hydroxyl group of 100 effects a nucleophilic displacement reaction on the nitrogen of the
oxime and the acetate salt makes the nitrogen of the oxime more conducive to this
displacement reaction.171 The acetamide-protecting group was eventually removed by
acidic hydrolysis. The synthesis is outlined in Scheme 10.
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Scheme 10. Synthesis of compound 90a
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N

x HCl

OCH3

90

a

Reagent: (1) Ac2O, EtOAc, 60 °C, 2 h; (2) room temperature, 24 h; (b) SOCl2, CH2Cl2,
room temperature, 1.5 h; (c) 1,4-dimethoxybenzene, AlCl3, ClCH2CH2Cl, reflux, 20 h; (d)
(1) hydroxylamine hydrochloride, NH4OAc, EtOH, reflux, 16 h; (2) Ac2O, 2 h, 60 °C; (e)
NaH (toluene washed), DMF, room temperature, 48 h; (f) (1) conc. HCl, EtOH, reflux, 3 h.
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b. Functional activity studies:
The functional activity assays of risperidone (3), ketanserin (42) and the hybrid compounds
84 and 85 were performed in Dr. Logothetis’ laboratory by Jason Younkin and Amr
Ellaithy, and were tested in the TEVC electrophysiological assay in the Xenopus laevis
oocyte heterologous expression system. As discussed earlier, the TEVC assay measures the
current at the GIRK4* channel associated with the 5-HT2A receptor (Figure 25).

In the preliminary studies, at a dose of 10 µM, risperidone (3), ketanserin (42) and
compound 84 antagonized the activity of 1 µM 5-HT and brought the Gαq-mediated
activity of 5-HT down to about 20%, 15% and 21%, respectively. Paliperidone (10 µM)
was also tested in the same assay system and it had an activity similar to risperidone by
bringing the activity of 5-HT (1 µM) down to 20%. However, compound 85 had relatively
little effect on the activity of 5-HT (Figure 35).
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Figure 35. The activity of risperidone, paliperidone, compounds 84 and 85, and ketanserin
in the presence of 5-HT (figures provided by Jason Younkin and Amr Ellaithy).

Compound 85 was thereafter tested by itself (in the absence of 5-HT) for Gαq-mediated
activity and in the very preliminary studies showed an activity of around 20% compared to
the activity of 5-HT (100%) (Figure 36).
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Figure 36. The positive efficacy shown by ketanserin and compound 85 (figures provided
by Jason Younkin and Amr Ellaithy).

However, ketanserin, which is an established antagonist at 5-HT2A was shown to have a
positive efficacy of 45% (Figure 36). This positive efficacy, as discussed previously for
risperidone and its deconstructed analogs, could be due to the activity of the compound at
the GIRK4* channel independent of the Gαq-mediated activity. This is under further
investigation.

c. Radioligand binding studies:
The radioligand binding assay was conducted in Dr. Javier González-Maeso’s laboratory
by Dr. José L. Moreno. As discussed earlier, these studies were performed in HEK293
cells with [3H]-ketanserin (2 nM) as the radioligand. Non-specific binding was determined
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in the presence of 10 µM methysergide and competition curves were generated and
analyzed by nonlinear regression to derive the dissociation constants (Ki values).

Risperidone (3), ketanserin (42) and their structural hybrids, compounds 84 and 85 were
tested in this assay system. They bound with high affinity with Ki values of 5.22 ± 1.40,
18.55 ± 1.78, 12.74 ± 1.50 and 0.96 ± 0.21 nM, respectively (Figure 37) (Table 5).
B

A

Ki = 18.55 ± 1.78 nM

Ki = 5.22 ± 1.40 nM

D

C
Compound 84

Compound 85

Ki = 12.74 ± 1.50 nM

Ki = 0.96 ± 0.21 nM

Figure 37. The binding affinity data for risperidone (A), ketanserin (B), compounds 84
(C), and 85 (D) (figures provided by Dr. José L. Moreno).
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Table 5. Biological activity of risperidone, ketanserin and their two hybrids.
Compounds

N O
O

N

Radioligand
binding assay,
Ki ±SEM
values (nM)

20

5.22 ± 1.40

15

18.55 ± 1.78

21

12.74 ± 1.50

85

0.96 ± 0.21

F

N

N

TEVC
electrophysiology
assay
[% activity of 5HT in presence of
the compounds]

CH3

Risperidone (3)
O
O
N

N
N
H

F

O

Ketanserin (42)
O
O
N

N
N

F

CH3

84
N O
O
N

N
N
H

F

O

85

*

The biological assay data for 84 and 85 are from two experimental determinations.
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3. Discussion:
The functional activity data suggests that the structural hybrids of risperidone and
ketanserin, compounds 84 and 85 have different activities at the receptor. Similar to
risperidone, paliperidone and ketanserin, compound 84 seems to antagonize the activity of
5-HT at the receptor, bringing it almost down to the baseline.

Compound 85 did not seem to affect the activity of 5-HT to a great extent. Also, when
tested by itself at the receptor, it gave a positive efficacy of ∼20% suggesting partial
agonist activity. Also judging by its activity in the presence of 5-HT, it can be suggested
that compound 85 shows potential to be a low potency partial agonist. However, dose
response curves for both hybrids would be needed to confirm this. In the same study
(Figure 36), ketanserin gives an activity of 45%, which as discussed earlier, could be due
to its activity at the GIRK4* channels. Although the same cannot be unequivocally said for
the hybrid, testing compound 85 at the GIRK4* channel as a negative control would tell us
how much of the activity is actually mediated through the Gαq pathway.

Radioligand binding affinity data suggests that the two hybrids bind with high affinity at
the 5-HT2A receptor. Compound 85, which has the left half of ketanserin and the right half
of risperidone binds with the highest affinity, almost 5-, 13- and 19-fold higher than
risperidone, 84 and ketanserin, respectively. The higher binding affinity of compound 85
suggests that the right half of risperidone (which is common to both, 85 and risperidone),
might be important for the binding affinity of risperidone. As the binding affinity of 85 is
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∼5-fold higher than risperidone, the quinazolinedione moiety might be contributing
towards enhancing the binding affinity.

Compound 85, which contained the left half of ketanserin, binds with ∼19 times higher
binding affinity compared to ketanserin. This suggests that the right half made certain
interactions that reinforce its binding activity at the receptor. Herndon et al. had reported
that the right half of ketanserin (4-fluorobenzoyl piperidine) was sufficient for binding at
the receptor, while the left half (quinazolinedione) enhances the binding.143 The
quinazolinedione could be strengthening the binding of compound 85 in a similar fashion,
such that the binding affinity of 0.96 nM could be a combined effect of the left and the
right halves of the compound.

Compound 84 binds at the receptor with ∼2 times lower binding affinity than risperidone.
As the binding affinity of the left half of risperidone has yet to be tested, we cannot make a
strong argument regarding which structural half is responsible for its binding affinity.
However, owing to its ∼13 fold lower binding affinity than compound 85, certain
speculations can be made. First, it lacks certain structural features that contribute to the
high binding affinity of 85 (0.96 nM). Second, the left half of 84 might not be contributing
to its binding affinity, unlike the quinazolinedine moiety of compound 85, which seems to
be bolstering the affinity (Herndon et al.).143 However, without the binding affinity of the
left half of compound 84, it is difficult to draw conclusions about the effect the two
structural halves have on the binding affinity of compound 85.
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C. MOLECULAR MODELING STUDIES:
1. Approach
Homology modeling and docking studies of risperidone and its deconstructed and
elaborated analogs were conducted to examine their binding modes at the orthosteric
binding site at the human 5-HT2A receptor. The different kinds of interactions with various
amino acids at the receptor would give us an idea of the relative importance of the
structural features making interactions. Moreover, we will gain a perspective into the
relative binding modes of risperidone and ketanserin at the 5-HT2A receptor, and to identify
any differences in their binding mode(s) (ligand receptor interactions), if they exist.
Binding affinity and functional data will be compared with the results from the docking
studies.
Furthermore, the possible role of the hydroxyl group of paliperidone was investigated, as
was the role of the fluoro group of risperidone.

As discussed earlier, the 5-HT2A receptor consists of seven transmembrane (TM) spanning
helices180 with an extracellular N-terminus and an intracellular C-terminus (Figure 38). The
human 5-HT2A protein subunit is about 52 kDa and is composed of 471 amino acids with
124 amino acids forming the extracellular domain (ECD), 159 amino acids forming the
TM, and 188 amino acids forming the intracellular domain (ICD).80 In addition, the protein
also has a DRY motif (D172, R173, Y174), a NPxxY motif and a PDZ-motif along with
two disulfide bridges formed by two sets of cysteine residues (i.e., C148 with C227 and
C350 with C353).80,181,182 There is evidence that the DRY-motif is important for
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maintaining receptor conformation, G-protein coupling/recognition and mutations of this
conserved sequence has led to agonist-independent constitutive activity in certain GPCRs
(rhodopsin, β2-adrenoceptors).183 The NPxxY motif is involved in stabilizing the active
conformation of the receptor after activation and the PDZ domain can bind to PDZ
proteins, which can influence almost all aspects of GPCR signaling, from ligand binding
and G-protein coupling to downstream signaling events.184,185

Figure 38. A model of the 5-HT2A receptor generated as a part of the current study.

As the crystal structure of the 5-HT2A receptor has not yet been solved, we had to rely on
homology with appropriate template proteins for a 3-dimensional view of the receptor.
Initially, before the 3-dimensional structures of the known neurotransmitter receptors were
resolved, graphical models of 5-HT2A receptors were built and analyzed using the structure
of bacteriorhodopsin, which is not a GPCR, but a light-dependent proton pump.180 These
models suffered from weak sequence homology and were highly dependent on
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computationally intensive dynamics simulations.180 Later on, bovine rhodopsin replaced
bacteriorhodopsin as the template.182,186 A breakthrough occurred in the field of homology
modeling with the resolution of the crystal structure of the class A aminergic GPCR β2adrenoceptor in 2007. 5-HT2A receptors share a sequence homology of approximately 40%
with β2-adrenoceptors (Table 6).186

Table 6. Initial template choices for homology modeling of 5-HT receptors adapted from
McRobb et al.186
Receptor

%Homology
Rhodopsin

β2 adrenoceptors

Adenosine A2A

5-HT1B

23

41

35

5-HT2A

22

40

30

5-HT2B

22

40

30

5-HT2C

23

42

30

The 5-HT2 family of receptors shares a homology of about 70% with each other.80 In 2013
the high-resolution crystal structure of the 5-HT2B receptor was solved (PDB ID: 4IB4, at
2.7 Å) in complex with the β-arrestin signaling-biased agonist ergotamine.187 The P-I-F
motif (located near the base of the ligand binding pocket, and involved in the
conformational changes in GPCRs after activation),187 undergoes a number of
conformational changes in response to an agonist, and showed a conformation similar to
that of the inactive β2-adrenoceptor (PDB ID: 2RH1).187,188 As our present investigation is
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focused on risperidone (with negative efficacy at the 5-HT2A receptor), which possesses a
high affinity for the inactive state of the 5-HT2A receptor, and because of the high sequence
homology of 70% between the two receptors, we used the crystal structure of the 5-HT2B
receptor as a template.

As a first step in building the homology models, the sequence of the target protein (5-HT2A
receptor) was aligned with the corresponding residues from the template (5-HT2B receptor)
using the CLUSTALX 2.1 program. As the sequence homology is quite high, most of the
residues or the nature of the residues (such as hydrophobic or polar), matched (Figure 39).
TM2$

TM1$
5"HT2B'
5"HT2A'
TM3$

TM4$

TM5$

TM7$

TM6$

Figure 39. Multiple sequence alignment between 5-HT2A and 5-HT2B receptors generated
by the software CLUSTALX 2.1.
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One hundred homology models were generated using the MODELLER v9.1 program;
these were further refined by adding hydrogens and bridging the disulfide connections on
SYBYL-X2.1. Ligands were docked using the programs GOLD Suite 5.2 and 5.3 and the
the interactions of the solutions of ketanserin in the present study were compared with
those reported in previously published homology models of 5-HT2A receptors and sitedirected mutagenesis data by our laboratory as well as other groups.189–193 The docked
solutions were re-scored with the HINT (Hydropathic INTeractions) program, which is
based on the experimental free energy information derived from log Po/w (the solvent
partition co-efficient for 1-octanol/water).194 The HINT studies will quantify the different
interactions each ligand makes with the receptor.

2. Results and discussion:
As a first step, the binding pocket of models generated as a part of our study was compared
to previously published 5-HT2A receptor homology models. The model with the highest
DOPE (Discrete Optimized Protein Energy) score as calculated by MODELLER was
chosen for this comparison. According to previously reported homology models,189–193 the
orthosteric binding pocket is located in the transmembrane region and is composed of
residues belonging to TM3, TM5, TM6 and TM7, such as D155 and S159 (TM3), S239
(TM5), W336, F339 and F340 (TM6), Y370 (TM7) and L228 and L229 (ECL2). Our
model conformed to these reported results (Figure 40).
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S239

TM6

F339

F340
TM5

D155
Y370

W367

S240
TM3

S159

TM7

Figure 40. An energy minimized model from the current study with the binding pocket
highlighted along with the residues constituting the binding pocket.

An energy-minimized complex of ketanserin with the 5-HT2A receptor is depicted in Figure
41. In addition to the ionic interaction of the ammonium ion in the piperidine ring of
ketanserin with the conserved aspartate residue (D155) in TM5, there were three additional
hydrogen bonds: S159 (TM3) with the p-fluorobenzoyl carbonyl oxygen, S131 (TM2) with
the N1 quinazolinedione nitrogen atom and S242 (TM5) with the p-fluorobenzoyl fluorine
atom (Figure 41). Additionally, ketanserin was surrounded with a bed of hydrophobic
residues: W151, V156 (TM3), F339, F340 (TM6), L228, L229 (ECL).
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B

TM5

S239
F339

TM6

A

S242

D155
TM3

S159

S131
TM2
Y370

C
ECL2

TM5

TM2
TM6

TM7

Figure 41. An energy-minimized ketanserin-receptor complex (A), interactions of
ketanserin (purple) with amino acids forming the binding pocket (B), and hydrophobic
residues, depicted as spheres, surrounding ketanserin (purple) in the binding pocket (C).

The interactions made by ketanserin in our models were compared to those considered
important in the literature models. The importance of these residues in the binding of
ketanserin was previously assessed by site-directed mutagenesis studies (Table 7). As
depicted in Figure 41 and Table 7, our model showed all the interactions reported to be
important, and more.
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Table 7. Site-directed mutagenesis data reported in the literature for the binding affinity of
ketanserin.191,192,195–198
Mutation

TM domain

Kd ± SEM
(nM)
-

Ki ± SEM (nM)
0.5 ± 0.2
No binding
No binding
No binding

Mutant/WT Reference
ratio
191
191
191
191

WT
D155A
D155N
D155Q

III
III
III

WT
D155N

III

-

0.8 ± 0.2
60 ± 1

75

192
192

WT
W336A
W367L
Y370A
F365L

VII
-

0.98
899
No binding
18.4
3.9

-

917.34
18.77
3.97

195
195
195
195
195

WT
F339A
F339L
F339Y
F340Y
F340A
F340L

VI
VI
VI
VI
VI
VI

0.4
4.6
9.8
2.8
29
0.9
0.3

-

11
24.5
7
72.5
2.25
0.75

196
196
196
196
196
196
196

WT
S159A
S159C

III
III

0.84
1.1
0.66

-

1.30
0.78

197
197
197

WT
F243A
F244A
S239A

V

-

2.3
10.4
6.7
1.5

4.52
2.91
0.65

198
198
198
198

Previously published models of the 5-HT2A receptor have described two possible binding
modes for ketanserin: one with the p-fluorobenzoyl fluorine atom pointing towards TM5199
and the second, with the fluorine atom pointing towards TM7182 (Figure 42). We observed
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both binding modes; however, the GOLD score of the model with the fluorine atom
pointing towards TM7 was low (51.32) compared to the GOLD score of the model with
the fluorine atom pointing towards TM5 (63.62), making this pose possible, but unlikely.
Also, the models reported in the literature were built using the crystal structure of bovine
rhodopsin (PBD ID: 4X1H) as the template (sequence homology: <22%).182,199 A higher
GOLD score coupled to a superior sequence homology of 70% with the template and
adherence to interactions considered important by site-directed mutagenesis, validated our
model (Figure 42).
TM5

A

TM6

S239

F339
TM2
S131

S242
S159

D155

TM3

B

Y370

C

TM6
TM2
TM5

TM6
TM7 TM2
TM7
TM3

TM3

Figure 42. The two binding modes of ketanserin: our model (A), literature models with the
fluorine atom pointing towards TM5 (B),199 and pointing towards TM7 (C).182
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Risperidone (3), paliperidone (7), ketanserin (42) and the analogs included in the
deconstruction and elaboration of risperidone/paliperidone (i.e., compounds 55-58, 60, 84,
85, and 90) were energy minimized before docking. Molecular docking was conducted
using the scoring function within the docking program GOLD Suite 5.2 and the binding
pocket was defined as being within a 10-Å radius surrounding the α-carbon atom of the
D155 residue in TM3. The docking solutions were divided into clusters (the cluster
docking script was provided by Dr. Philip D. Mosier) based on the binding poses. The
clusters were analyzed and the models were evaluated for each ligand, based on the GOLD
fitness scores, and interaction of the ammonium ion of the ligands with D155. For models
selected (∼16 models for every ligand), based on the fitness score and the interactions, the
solutions were merged with the models and energy-minimized using the Tripos Force field
function in SYBYL-X2.1 to optimize the interactions. These models were further rescored
by conducting HINT studies. The final model for each ligand was chosen based on the
most optimal HINT score.

a. Deconstruction of risperidone/paliperidone:
The GOLD and HINT scores for the models chosen for risperidone, paliperidone and their
deconstructed analogs (55-58) are summarized in Table 8. In the models chosen,
risperidone (3), paliperidone (7) and all the deconstructed analogs had similar binding
modes at the receptor, i.e., their 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole portion was
oriented towards TM5 (see Figure 44).
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Table 8. Risperidone and its deconstructed analogs: Ligands and the models chosen based
on the GOLD and HINT scores.
Ligand

GOLD
score

Polar

Hydrophobic

D155

S159

S242

N363

1225

Total
HINT
score
1204

Risperidone
(3)

64.62

1523

737

374

82

22

Paliperidone
(7)

58.19

1361

1026

873

732

368

67

210

55

48.73

1593

430

1366

1370

28

115

0

56

54.82

1250

1165

1093

740

379

87

6

57

53.99

1464

792

1445

682

258

55

352

58

46.56

1128

626

865

970

67

79

0

A previously published model of the 5-HT2A receptor had described another mode of
binding for risperidone where the 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole portion was
oriented towards TM7200 (Figure 43) (similar to ketanserin, Figure 42).
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ECL2$

A
S239$

TM6$

TM5$

L229$

B

L228$

ECL2$

F340$
TM5$
T134$

S242$
V156$
S159$

TM3$
D155$

Y370$
TM7$

S131$ TM2$

TM7$
TM6$

Figure 43. The binding modes of risperidone: our model with the fluorine atom pointing
towards TM5 (A), and literature model with the fluorine atom pointing towards TM7
(B).200

Similar to ketanserin, we observed both binding modes, however, the GOLD score of the
model with the fluorine atom pointing towards TM7 was low (51.55) compared to the
GOLD score of the model with the fluorine atom pointing towards TM5 (64.02). Also, the
model reported in the literature was built using the crystal structure of β2 adrenergic
receptor (PBD ID: 2RH1) as the template (sequence homology: 40%), while our model
was built using the crystal structure of the 5-HT2B structure as the template (sequence
homology: 70%).

117

A
TM6

ECL2

TM5

TM7
N2

O1

B

TM2
TM3

TM6

ECL2

L229

TM5

S239

S131
S242

O1

N2

V156

I206

T160

S159
TM3

D155

TM7

TM2

Y370

Figure 44. The binding orientation of risperidone (magenta), paliperidone (cyan) and their
deconstructed analogs 55 (green), 56 (orange), 57 (yellow), and 58 (teal) at the 5-HT2A
receptor (A), and their interactions with amino acids in the binding pocket (B).
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Molecular modeling studies suggested that both halves of risperidone formed strong
interactions at the receptor, while hydrophobic interactions predominated at the left half
made up of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system; polar
interactions seemed to dominate the front on the right half, consisting of the 6-fluoro-(3piperidinyl)benz[d]isoxazole moiety.

All ligands formed an ionic bond with the conserved D155 (TM3), which is involved in
anchoring the terminal amine moiety of tryptamines at the receptor.195 S159 (TM5) formed
a bifurcated hydrogen bond with the 6-fluoro-(3-piperidinyl)benz[d]isoxazole O1 and N2
atoms of all the deconstructed analogs (Figure 44). Bifurcated hydrogen bonds (H-bond)
occur when one hydrogen atom simultaneously forms H-bonds to two other H-bond
acceptors.201 Compound 55 formed a second bifurcated H-bond interaction (O1 and N2 in
6-fluorobenzisoxazole) with S242 (TM5) (Figure 45). From the radioligand binding data at
the 5-HT2A receptor for the deconstructed analogs of risperidone (3) (Table 4), we can
conclude that there is ∼15-fold difference in the binding affinity of risperidone and its
smallest deconstructed analog 55. This suggests that even after removing the entire left
half of risperidone (Ki = 5.22 nM), the compound 55 retained good binding affinity (Ki =
75.75 nM). As seen from Figure 45, compound 55, although devoid of certain hydrophobic
interactions made by the left half of risperidone, formed two bifurcated H-bonds (S159 and
S242) that this could be supported by its retention of affinity at the receptor.
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A

TM6

ECL2

F339

L229

S239
TM5
S242

O1

N2
V156

S131

TM3
Y370

I206

D155

T160

S159

TM2

TM7

B

D155

V366
N-Methyl group of
59

W151

Figure 45. The bifurcated H-bonds by compound 55 with S242 (TM5) in comparison to
risperidone (magenta) (A), and the additional hydrophobic interactions made by compound
58 (B).
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Strong hydrophobic interactions were observed between compound 58 and W151 (TM3)
and V366 (TM7) that were lacking with 55 and the other deconstructed analogs (Figure
45). Radioligand binding studies indicated that 58 has a high binding affinity
(Ki = 18.77 nM), and although it lacks certain structural features of risperidone, it binds
with only ∼3-fold lower affinity than risperidone. Compounds 55 and 58 differ only in a
single N-methyl group, but compound 58 binds with ∼4-fold higher affinity. The N-methyl
group increased the binding affinity of 55 by ∼4-fold and the extra hydrophobic
interactions made by 58 might be contributing.

Functional data suggested that compound 57 enhanced the activity of 5-HT and could
potentially behave as a superagonist or an ago-allosteric modulator. Its high binding
affinity (Ki = 35.20 nM) indicated that it might exert at least part of its activity at the
orthosteric site of the 5-HT2A receptor. Modeling studies showed that the compound
lacking the carbonyl group 57 formed a strong hydrogen bond with N363 (TM7) (Table 8
and Figure 46) with the ammonium ion in its second piperidine ring (risperidone has this
nitrogen atom as a part of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring
system). This suggests that 57 is capable of forming additional interactions at the receptor
close to the binding pocket. Although it cannot be said with certainty at this moment,
compound 57 might potentially be binding at two sites (orthosteric as well as a potential
allosteric site) simultaneously.
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A

N363

B

N363

Figure 46. The interaction of compound 57 (yellow) with N363 (TM7) compared to
risperidone (magenta) (A), and a comparison of the binding pose of risperidone (magenta)
and paliperidone (cyan) (B).

Molecular modeling studies showed that the hydroxyl group of paliperidone (the only
point of difference between risperidone and paliperidone) did not directly participate in
hydrogen bonding (Figure 46). This could explain why the two compounds have almost
identical binding affinities at the receptor as shown by literature (risperidone: Ki = 0.16 nM
and paliperidone: Ki = 0.25 nM).202
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b. Elaboration of risperidone/paliperidone:
i. Comparison of the binding modes of risperidone and ketanserin:
In order to gain insight into the functional and binding differences observed with
risperidone (3) and ketanserin (42), we conducted a comparative study of their binding
modes at the receptor and their respective molecular interactions with specific amino acids
lining the binding pocket. Furthermore, we docked their structural hybrids, compounds 84
and 85 to get a better insight into the two structural halves of risperidone and ketanserin.
The GOLD scores and the HINT scores for the chosen models for risperidone, ketanserin
and 84 and 85 are summarized in Table 9.

Table 9. Risperidone, ketanserin and their structural hybrids: Ligands and the models
chosen based on the GOLD and HINT scores
Ligand

GOLD
score

Polar

Hydrophobic

D155

S159

S242

1225

Total
HINT
score
1204

Risperidone
(3)
Ketanserin
(42)
84

64.62

1523

737

374

82

63.62

1658

900

1112

724

374

169

61.16

1387

1054

1044

733

395

73

85

63.09

1547

870

1121

745

369

12

All four ligands had a similar binding pose at the receptor and the hybrid compounds 84
and 85 made the ionic interaction with D155 as discussed earlier with ketanserin and
risperidone (Figure 47).
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TM6

L229

S239
ECL2

TM5

F339

S242
S131
D155
S159

TM3

TM2
Y370

Figure 47. The similar binding pose of risperidone (magenta), ketanserin (purple),
compounds 84 (gold) and 85 (dark green) at the receptor.

There was a difference in the manner in which ketanserin (42) docked at the receptor
compared to risperidone (3) and compounds 84 and 85. The right half of ketanserin (pfluorobenzoyl) was oriented upwards compared to the other ligands to form a stronger
interaction with S242 from TM5 (Table 9) (Figure 48).
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S242

Figure 48. A snapshot of the differences in the orientation of the common p-fluorobenzoyl
moiety of ketanserin (purple) and compound 84 (gold) at the receptor.

Both the hybrid compounds have certain structural remnants of ketanserin – compound 84
has the right half of ketanserin and compound 85 has the left half of ketanserin (Figure 32);
however, both had a better overlap with risperidone in their docking solutions (Figure 49).
In fact, the common quinazolinedione portion of ketanserin and compound 85 seemed to
bind differently. The quinazolinedione ring of 85 seemed to rotate by 180° around the
horizontal axis to overlap completely with the 6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4one ring system of risperidone (Figure 49). Radioligand binding bolstered this observation,
with compound 85 (Ki = 0.96 nM) having an almost identical binding affinity with
risperidone (Ki = 5.22 nM).

Additional hydrophobic interactions were observed between risperidone and the residues
I135, I152, L229 (ECL2) and V366 on the receptor. These interactions, though absent in
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ketanserin, were present in both hybrid compounds, suggesting a preference of binding
similar to risperidone rather than ketanserin.
A

C
B

Figure 49. The alignment of the hybrid compounds 84 (gold) and 85 (dark green) with
risperidone (magenta) (A), differences in the orientation of the common quinazolinedione
moiety of ketanserin (purple) and compound 85 (dark green) at the receptor (B), and the
perfect alignment of the left halves of risperidone (magenta) and compounds 84 (gold) and
85 (dark green) (C).
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ii. Effect of substituents on the benzisoxazole ring:
As discussed earlier, removal of the p-fluorobenzoyl fluorine atom decreased the binding
affinity of certain deconstructed analogs of ketanserin (Figure 22).143 In our molecular
modeling studies all the ligands seemed to dock orienting their fluoro substituent towards
S242 (TM5). Furthermore, the HINT studies suggested the formation of a potential
hydrogen bond between the fluorine atom and S242 for all compounds.

Hence, we conducted molecular modeling studies on compounds 60 (lacking the fluoro
group) and 90 (bearing a 5-OCH3 group) and compared their binding modes and molecular
interactions with the fluoro substituent of compound 55 (Figure 50) to determine the
importance of the fluoro substituent to examine the effect of substituents (or the absence of
them) and the position of the substituents on the benzisoxazole ring, on the polar and
hydrophobic interactions of the benzisoxazole ring system.
N O

N O

H

N

F

55

H

N

60

N O

H

N

90

OCH3

Figure 50. Structural comparison for the study of the effect of substituents on the three
benzisoxazoles.

The three compounds 55, 60, and 90 had a similar binding mode at the receptor (Figure
51). Despite being structurally indistinguishable other than for the substituents, they did
not align perfectly at the receptor and the source of the misalignment seemed to stem from
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the interactions made by the substituents on the benzisoxazole ring or the lack of
substituents (Figure 51).
B

ECL2
L229

A

N343

TM6

TM5
I152

F339

D155
S239

TM3
V156

S159
S242

Figure 51. The binding modes of the three benzisoxazoles, 55 (green), 60 (pink) and 90
(gray) (A), and their molecular interactions with the orthosteric site amino acids (B).

All three ligands formed the indispensible ionic interaction with D155 from TM3 and the
bifurcated H-bond with S159 (with their 6-fluoro-(3-piperidinyl)benz[d]isoxazole O1 and
N2 atoms). As discussed earlier for compound 55, S242 seemed to form a bifurcated Hbond with compounds 60 and 90 as well. The desfluoro compound 60 seemed to be closer
to S242 and made a stronger interaction with S242 (Table 10).
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Table 10. Role of substituents and their position on the binding interaction of
benzisoxazole ring: Ligands and the models chosen based on the GOLD and HINT scores
Ligand

GOLD
score

Polar

Hydrophobic

D155

L229

S239

S242

430

Total
HINT
score
1366

55

48.73

1593

1370

26

33

115

60

46.76

1862

342

1463

1548

18

1

199

90

46.74

2022

638

1654

1300

121

0
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The difference in substituents was reflected in the interactions made by the three
compounds and these were quantified by HINT studies (Table 10). Compound 55 formed a
weak hydrogen bond with S239 from TM5, whereas compounds 60 and 90 did not form
this interaction. The methoxy group of 90 made a strong hydrophobic interaction with
L229 from ECL2, which was marginal for 55 and 60. The O atom of the methoxy group of
90 also formed a weak hydrogen bond with N343 (TM6) and this interaction was lacking
by both, 55 and 60.

Radioligand binding data would be more conclusive regarding the role played by the
presence (or absence) of substituents and on the position of the substituents on the
benzisoxazole ring. Molecular modeling and HINT studies suggested some differences in
their specific interactions. Although 5-methoxy compound 90 utilized more hydrophobic
and hydrogen bonds than 55 and 60, the lack of substituents seemed to orient compound 60
more towards S242 (TM5), compared to 55 and 90 (Figure 51).
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CHAPTER V: CONCLUSION

The primary intent of the current investigation was to study the structure of risperidone
with respect to its inhibitory action at 5-HT2A receptors and to determine the minimum
structural features of risperidone responsible for its antagonist activity. This was probed by
the medicinal chemistry principles of deconstruction and elaboration. The current
investigation also focused on the deconstruction of paliperidone (9-OH risperidone).
Structurally, risperidone is a deconstructed analog of paliperidone.

The systematically deconstructed analogs of risperidone (55-58) were tested for their
functional activity in two assays, which gave differing results. Although the calcium
imaging assay suggested that the compounds have antagonist activity, the more sensitive
TEVC assay indicated that the compounds were low-efficacy partial agonists – with the
exception of compound 57, which at a higher concentration of 50 µM seemed to possess
activity greater than the endogenous ligand 5-HT. Compound 57 could either be a potential
superagonist, an allosteric modulator or the compound might be activating the GIRK4*
channels independent of the 5-HT2A receptor, or a combination of two or more of these
actions. These results were subjected to further investigation by testing compound 57 at the
GIRK4* channel in the presence and absence of the 5-HT2A receptor (see Appendix A).

130

The most striking feature of the functional activity data was the fact that in the TEVC
assay compounds 55 and 58 had inhibitory activity comparable to that of risperidone,
implying that the entire structure of risperidone might not be required for its antagonist
activity. As such, this (coupled with our previously published data on 55164) suggest that
the benzisoxazolylpiperidine moiety represents a pharmacophore for the 5-HT2A antagonist
action (and binding) of risperidone-type agents.

With speculation about the functional activity data in hand and speculations about the
potential ‘superagonist’ or ‘ago-allosteric’ properties of compound 57 the compounds were
tested in a radioligand binding assay to determine if the functional activity observed was
due to their effect at 5-HT2A receptors. Risperidone and its deconstructed analogs bind with
high affinity at the receptor, which suggested that compound 57 exerts at least part of its
activity by binding at the orthosteric site of the receptor.

The radioligand binding data of the deconstructed analogs suggested that the N-methyl
compound 58 (Ki = 18.77 nM), which has the highest binding affinity among all the
deconstructed analogs of risperidone (55-58), was comparable to risperidone (Ki = 5.22
nM). This means that the entire structure of risperidone is not important for its affinity at
the receptor, and that the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
ring system can be removed (along with the hydrophobic interactions it makes) and the
hydrophobic interactions made by the free N-methyl group can substitute for those
interactions. Molecular modeling studies showed that the N-methyl group of compound 58
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forms certain hydrophobic interactions (V366 and W151) (Figure 45). These interactions
were not exhibited by even the longer deconstructed analogs 56 and 57.

The comparative study between risperidone (Ki = 5.22 nM) and ketanserin (Ki = 18.55 nM)
brought out certain differences in the way risperidone and ketanserin bind at the receptor.
Compound 85, which has the left half of ketanserin and the right half of risperidone had
the highest affinity at the 5-HT2A receptor, almost 5-, 13-, and 19-fold higher than
risperidone, 84 and ketanserin, respectively. This suggested that the interactions formed by
85 are optimal for high binding affinity. One conclusion that can be drawn from the higher
binding affinity of compound 85 is that the right half of risperidone might be important for
its binding affinity at the 5-HT2A receptor. As 85 and risperidone differ in their left halves
(85 has the quinazolinedione moiety), the quinazolinedione moiety of 85 might be
contributing towards the binding affinity and enhancing it.

Herndon et al.143 had previously reported that the left half of ketanserin, 2,4quinazolinedione, contributed to or enhanced the affinity of ketanserin and the 2,4quinazolinedione moiety by itself bound poorly at the receptor (Ki = 10,000 nM). It can be
speculated from this information that the right half of compound 85 might be sufficient to
maintain affinity at the receptor and the left half (the 2,4-quinazolinedione moiety) could
be reinforcing the affinity. A comparison of the binding affinities of compounds 55 (Ki =
75.75 nM), 85

(Ki = 0.96 nM) and risperidone (Ki = 5.22 nM) indicates that the

quinazolinedione moiety might be a better contributor towards high binding affinity at
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5-HT2A receptors than the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
ring system of risperidone.
The functional activity data of the hybrid compounds suggested that compound 85 is a
partial agonist at the 5-HT2A receptor. The observed efficacy could be due to its activity at
GIRK4* entirely that masks the potential antagonist activity of the compound (thus
making it a potential partial agonist; Figure 27) or a combination of the two (making it a
low-efficacy partial agonist). However, with the binding affinity data in hand, if we
consider the current efficacy as the Gαq-mediated activity at 5-HT2A receptors, compound
85 shows potential to be a low-efficacy partial agonist. However, both its structural halves
are composed of ligands (left half: ketanserin and right half: risperidone), which are known
to be antagonists at the 5-HT2A receptor.

According to previously published reports the quinazolinedione moiety can be a part of
agonists, partial agonists or antagonists, depending upon the moiety attached to the other
end (Figure 52). In fact, RH-34 (103) is known as a selective, potent partial agonist at 5HT2A receptors (Figure 52).
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Figure 52. The range of efficacies (intrinsic activities) that the quinazolinedione moiety
can be a part of. The intrinsic activity (i.a.) was measured using either rat tail artery (RTA)
or rat jugular vein (RJV).203,204

Thus the quinazolinedione moiety does not seem to influence the action of the compounds
(Figure 52) and the action is likely determined by the moiety linked to it or the functional
group on those moieties. The functional activity of compound 85, (which has the 2,4quinazolinedione moiety as its left half) could be influenced by its right half, which is 6fluoro-(3-piperidinyl)benz[d]isoxazole or compound 55. The functional activity data as it
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currently stands, could imply that 85 is a low-efficacy partial agonist or it is an antagonist
(if the efficacy shown is due to activity at GIRK4*). We can speculate the same about
compound 55. If 85 and 55 are antagonists (Iwamura et al.164 had reported 55 to be an
antagonist), it suggests that the quinazolinedione moiety in 85, as portrayed for other
quinazolinedione-containing compounds (Figure 52), might not influence its action and the
activity could be due to the 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety attached to it.

Compound 84 shows a functional activity similar to risperidone in the TEVC assay system
(Figure 35). However, as the binding affinity and functional activity of 2-methyl-6,7,8,9tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system is forthcoming, we cannot
conclude on the structural half contributing to its activity. However, there is literature
evidence that the 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety is a more potent
antagonist at 5-HT2A receptors than the 4-fluorobenzoylpiperidine moiety. As the current
functional data (Figure 35) indicates that 84 antagonizes the 5-HT mediated activity more
potently than 85, this suggests that perhaps the left half of 84 (2-methyl-6,7,8,9-tetrahydro4H-pyrido[1,2-a]pyrimidin-4-one ring system) could be influencing the activity of this
compound.

Forthcoming binding affinity data and functional activity studies will guide us as regards
making a conclusive argument about the precise role of various structural elements of
risperidone in its activity at the receptor. However, with the biological data currently in
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hand, it does seem that the entire intact structure of risperidone might not be required for
its activity and its affinity at 5-HT2A receptors.

The ability of compound 55 to crosstalk in a system co-expressing 5-HT2A receptors and
mGlu2 receptors is promising in terms of the fact that established inverse agonists at 5HT2A receptors such as clozapine and risperidone also exhibit this crosstalk. It would mean
that this portion of risperidone, could be sufficient for its inverse agonist activity at 5-HT2A
receptors.
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CHAPTER VI: EXPERIMENTALS

A. Synthesis:
Melting points (mp) were measured on the Thomas Hoover melting point apparatus and
are uncorrected. Proton NMR (1H NMR) spectra were recorded with a Bruker ARX 400
MHz spectrometer using trimethylsilane (TMS) as an internal standard, with peak
positions indicated by parts per million (δ). Infrared spectroscopy was conducted on a
Thermo Nicolet iS10 FT-IR. Electrospray ionization-mass spectrometry studies were
conducted using a Waters Acquity TDQ (tandem quadrupole) spectrometer in positive ion
mode. Elemental analyses (CHN) determined the purity of the compounds and was
performed by Altantic Microlab Inc. and the obtained values were within 0.4% of
theoretical values. Reactions were monitored by thin-layer chromatography (TLC) on
silica gel GHLF plates (250 µm, 2.5 x 10 cm; Analtech Inc. Newark, DE), and flash
chromatography was performed on a CombiFlash Companion/TS (Teledyne Isco Inc.
Lincoln, NE) using packed silica gel (Silica Gel 230-400 mesh) columns (RediSep Rf
Normal-phase Silica Flash Column, Teledyne Isco Inc., Lincoln, NE).
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6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole hydrochloride (55).
Compound 80 (0.10 g, 0.40 mmol) was added to a stirred solution of HCl (12 N, 0.14 mL)
and EtOH (7.0 mL) under an N2 atmosphere. The reaction mixture was heated at reflux for
3 h and allowed to stand at room temperature for 48 h to afford a buff-colored solid that
was recrystallized from EtOH/H2O to yield 0.02 g (18%) of compound 55 as a white solid:
mp 302-304 °C (lit.171 302-306 °C) 1H (DMSO-d6): 2.07-2.52 (m, 6H, CH2), 3.09 (s, 2H,
CH2), 3.34-3.58 (m, 1H, CH), 7.33 -7.39 (m, 1H, ArH), 7.73-7.76 (m, 1H, ArH), 8.11-8.14
(m, 1H, ArH), 9.03 (br s, 1H, NH+).

4-(4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)-1-(piperidin-1-yl)butan-1-one
hydrochloride (56).
Compound 67 (0.22 g, 1.14 mmol) and 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole (0.25
g, 1.14 mmol) were added to a stirred solution of K2CO3 (0.31 g, 2.26 mmol) and KI (few
crystals) in anhydrous MeCN (5 mL). The reaction mixture was allowed to stir in a screwcap vial at 88 °C for 16 h. The solvent was evaporated under reduced pressure; the residue
was suspended in H2O and extracted with CHCl3 (3 x 15 mL). The combined organic
portions were washed with H2O (3 x 10 mL), dried (Na2SO4) and evaporated under
reduced pressure to yield a buff-colored solid. The solid was dissolved in EtOH (5 mL)
and the solution was cooled to 0 °C. A saturated solution of gaseous HCl in Et2O (2 mL)
was added and the mixture was allowed to stand at room temperature for 3 h. The solvent
was evaporated to yield a white solid that was recrystallized from EtOH to yield 0.01 g
(3%) of compound 56 as a tan-colored solid: mp 216-218 °C (This compound was
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previously prepared in our laboratory as RHV-023 but has not been reported 207-210 °C)
1

H (DMSO-d6): 1.43-1.69 (m, 4H, CH2), 1.82-2.10 (m, 6H, CH2), 2.21-2.24 (m, 2H, CH2),

2.82-2.88 (m, 2H, CH2), 2.82-2.88 (m, 1H, CH), 3.23-3.26 (m, 2H, CH2), 3.40-3.52 (m,
2H, CH2), 3.63-3.66 (m, 2H, CH2), 3.98-4.02 (m, 2H, CH2), 4.48-4.51 (m, 2H, CH2), 7.297.38 (m, 1H, ArH), 7.70-7.76 (m, 1H, ArH), 8.05-8.18 (m, 1H, ArH), 10.17 (br s, 1H,
NH+) Anal Calcd for (C21H28FN3O2·HCl·0.5H2O) C, 60.21; H, 7.02; N, 9.77. Found: C,
60.32; H, 7.22; N, 10.03.

6-Fluoro-3-(1-(4-(piperidin-1-yl)butyl)piperidin-4-yl)benz[d]isoxazole (57).
A 1M solution of BH3 in THF (1.41 mL) was added to a stirred solution of the free base of
4-(4-(6-fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)-1-(piperidin-1-yl)butan-1-one (56)
(0.13 g, 0.35 mmol) in anhydrous THF (4 mL) at 0 °C (ice-bath). The reaction mixture was
allowed to warm to room temperature and stirring was continued for 10 h. The reaction
mixture was carefully quenched with 6 M aqueous HCl (0.40 mL, vigorous bubbling
occured) and heated at reflux for 1 h. The mixture was allowed to cool to room
temperature and basified with 1N aqueous NaOH (2 mL). H2O (10 mL) was added and the
aqueous layer was extracted with EtOAc (3 x 15 mL). The organic portion was combined,
dried (Na2SO4), and solvent was removed under reduced pressure to give an oily residue.
The oily residue was dissolved in absolute EtOH and HCl-anhydrous Et2O was added to
afford a solid. Recrystallization from absolute EtOH/anhydrous Et2O gave 0.04 g (26%) of
57 as yellow crystals: mp 270-273 °C; 1H-NMR (DMSO-d6: salt) δ 1.37 (m, 1H, CH2),
1.68-1.78 (m, 10H, CH2), 2.17-2.20 (m, 2H, CH2), 2.38-2.53 (m, 2H, CH2), 2.83 (m, 2H,
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CH2), 3.01-3.10 (m, 7H, CH, CH2), 3.36-3.46 (m, 1H, CH2), 3.58-3.61 (m, 2H, CH2), 7.32
(td, J = 9.1,2.0 Hz, 1H, ArH), 7.71 (dd, J = 9.0, 1.9 Hz, 1H, ArH), 8.25 (dd, J = 8.6, 5.4
Hz, 1H, ArH), 10.33 (br s, 1H, NH), 11.06 (br s, 1H, NH) Anal. Calcd
(C21H30FN3O·2HCl·0.25H2O) C, 57.73; H, 7.50; N, 9.62. Found: C, 57.36; H, 7.21; N,
9.30.

6-Fluoro-3-(1-methylpiperidin-4-yl)benz[d]isoxazole hydrochloride (58).
6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole (the free base of compound 55) (0.20 g, 0.90
mmol) was added to a stirred solution of HCOOH (0.2 mL, 5.45 mmol) and HCHO (0.2
mL, 5.45 mmol) in EtOH under an N2 atmosphere. The reaction mixture was heated at
reflux for 10 h and the solvent was evaporated to yield a white-colored solid. The solid was
dissolved in EtOH (5 mL) and cooled to 0 °C. A saturated solution of gaseous HCl in Et2O
(2 mL) was added and the mixture was allowed to stand at room temperature for 3 h. The
solvent was evaporated to yield a white solid that was recrystallized from EtOH to yield
0.01 g (4%) of 58 as a white solid: mp 218-220 °C (This compound was previously
prepared in our laboratory as RHV-008 but has not been reported 225-227 °C) 1H (DMSOd6): 2.20-2.25 (m, 4H, CH2), 2.20-2.23 (m, 1H, CH), 2.80 (s, 3H, CH3), 3.09-3.19 (m, 2H,
CH2), 3.53-3.56 (m, 2H, CH2), 7.33-7.38 (m, 1H, ArH), 7.73-7.75 (dd, J = 2, 8 Hz, 1H,
ArH), 8.15-8.18 (m, 1H, ArH), 10.64 (br, s, 1H, NH+) Anal Calcd for
(C13H15FN2O·HCl·0.5H2O) C, 55.82; H, 6.13; N, 10.01. Found: C, 55.50; H, 6.08; N,
9.69.0
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(±)4-(4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)-1-(3-hydroxypiperidin-1-yl)
butan-1-one hydrogen oxalate (59).
Compound 75 (0.37 g, 1.82 mmol) and 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole (the
free base of compound 55) (0.40 g, 1.82 mmol) were added to a stirred solution of K2CO3
(0.50 g, 3.63 mmol) and KI (few crystals) in MeCN (4 mL). The reaction mixture was
allowed to stir in a screw-cap vial for 45 h at 88 °C, cooled to room temperature and the
excess solvent was evaporated under reduced pressure to afford a white solid. The residue
was suspended in H2O (10 mL) and extracted with CHCl3 (3 x 25 mL). The combined
organic portion was washed with H2O (3 x 15 mL), brine (5 mL), dried (Na2SO4) and
evaporated under reduced pressure to yield a pale yellow-colored oil, which was purified
by flash chromatography (silica gel; CHCl3/MeOH; 9.5:0.5) to afford a colorless oil. The
oil was dissolved in EtOAc (5 mL) and cooled to 0 °C. A saturated solution of oxalic acid
(1.2 eq) in Et2O was added and the reaction mixture was allowed to stir at room
temperature overnight. The precipitate was collected by filtration to yield a white solid,
which upon recrystallization from EtOH/Et2O afforded 0.03 g (4%) of 59 as a white solid:
mp 182-184 °C. 1H NMR (DMSO-d6): 1.31-1.41 (m, 2H, CH2), 1.65-1.86 (m, 4H, CH2),
2.12-2.24 (m, 4H, CH2), 2.40-2.70 (m, 2H, CH2), 2.40-2.70 (m, 1H, CH), 3.00-3.18 (m,
6H, CH2), 3.33-3.49 (m, 6H, CH2), 7.30-7.33 (t, J = 12 Hz, 1H, ArH), 7.70-7.72 (d, J = 8
Hz, 1H, 1ArH), 7.89-8.19 (m, 1H, ArH) Anal Calcd for (C21H28FN3O3·C2H2O4) C, 57.61;
H, 6.31; N, 8.76. Found: C, 57.57; H, 6.26; N, 8.58. MS calculated: [M+H]+ = 390.2187,
MS found: [M+H]+ = 390.2195.
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3-(Piperidin-4-yl)benz[d]isoxazole hydrochloride (60).
A solution of KOH (85%) was added to a stirred solution of compound 83 (0.14 g, 0.45
mmol) in absolute EtOH (3 mL) under an N2 atmosphere. The reaction mixture was heated
at reflux for 48 h and cooled to room temperature. The solvent was removed under reduced
pressure and the aqueous mixture was extracted with EtOAc (3 x 15 mL). The combined
organic portion was dried (Na2SO4), and evaporated under reduced pressure to yield a
brown-colored oil. The oil was dissolved in absolute EtOH (2 mL) and cooled to 0 °C. A
saturated solution of gaseous HCl in Et2O (2 mL) was added and the reaction mixture was
allowed to stir at room temperature overnight. The precipitate was collected by filtration to
yield a buff-colored solid, which upon recrystallization from MeOH-Et2O afforded 0.02 g
(20%) of 60 as a white solid: mp 304-306 °C (lit.171 313-315 °C) 1H NMR (DMSO-d6):
2.18-2.19 (m, 4H, CH2), 2.18-2.19 (m, 1H, CH) 3.10-3.17 (m, 2H, CH2), 3.38-3.47 (m, 2H,
CH2), 7.40-7.44 (t, J = 8 Hz, 1H, ArH), 7.67-7.69 (m, 1H, ArH), 7.74-7.76 (m, 1H, ArH),
8.07-8.09 (d, J = 8 Hz, 1H, ArH), 9.15 (s, 1H, NH, D2O ex).

3-(1-Methylpiperidin-4-yl)benz[d]isoxazole hydrochloride (61).
A solution of KOH (85%) was added to a stirred solution of compound 82 (0.20 g, 0.78
mmol) and hydroxylamine hydrochloride (0.11 g, 1.67 mmol) in ethoxyethanol (3 mL)H2O (2 mL) under an N2 atmosphere. The reaction mixture was heated at reflux for 6 h,
cooled to room temperature, quenched by addition of ice-H2O (50 mL) and extracted with
Et2O (3 x 40 mL). The combined organic portion was washed with H2O (3 x 20 mL), brine
(5 mL), dried (Na2SO4) and evaporated to yield an orange-colored oil. The oil was
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dissolved in EtOH (2 mL) and cooled to 0 °C. A saturated solution of gaseous HCl in Et2O
(2 mL) was added to yield a white solid, which upon recrystallization from EtOH/Et2O
afforded 0.04 g (23%) of 61 as a white solid: mp 248-250 °C (lit.171 250-252 °C) 1H NMR
(DMSO-d6): 2.25-2.35 (m, 4H, CH2), 2.25-2.35 (m, 1H, CH) 2.73-2.88 (m, 3H, CH3),
3.09-3.25 (m, 2H, CH2), 3.43-3.62 (m, 2H, CH2), 7.40-7.44 (t, J = 8 Hz, 1H, ArH), 7.657.69 (m, 1H, ArH), 7.74-7.76 (m, 1H, ArH), 8.08-8.21 (m, 1H, ArH), 10.95 (s, 1H, NH,
D2O ex).

4-Chloro-1-(piperidin-1-yl)butan-1-one (67).
Piperidine (68) (1.2 mL, 11.54 mmol) was added in a dropwise manner to a stirred solution
of Et3N (1.2 mL, 11.54 mmol) in CH2Cl2 (25 mL) and the reaction micture was cooled to
0 °C under an N2 atmosphere. A solution of 4-chlorobutyryl chloride (1.5 mL, 11.74
mmol) in CH2Cl2 (5 mL) was added and the reaction mixture was allowed to stir at room
temperature for 75 h and washed with H2O (2 x 25 mL). The organic portion was dried
(Na2SO4) and evaporated under reduced pressure to yield a yellow-colored oil, which was
purified by vacuum distillation to yield 1.00 g (45%) of 67 as a pale yellow-colored oil: bp
103 °C at 0.02 psi.

(±)4-Chloro-1-(3-hydroxypiperidin-1-yl)butan-1-one (74).
A solution of 4-chlorobutyryl chloride (1.39 g, 9.88 mmol) in CH2Cl2 (20 mL) was added
in a dropwise manner to a solution of (±)3-hydroxypiperidine (69) (1.00 g, 9.88 mmol) and
Et3N (1.01 g, 9.98 mmol) in anhydrous CH2Cl2 (25 mL). The reaction mixture was allowed
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to stir at room temperature for 16 h, quenched by addition of H2O (20 mL), and extracted
with CH2Cl2 (3 x 15 mL). The combined organic portion was washed with H2O (3 x 20
mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield a
yellow-colored oil, which was purified by flash chromatography (silica gel; CHCl3/MeOH;
9.5:5) to afford 0.65 g (32%) of 74 as a colorless oil, which was used without further
characterization in the preparation of compound 59.

N-Formylpiperidine-4-carboxylic acid (76).
A stirred solution of HCOOH (15 mL, 371.63 mmol) and Ac2O (35 mL, 371.63 mmol)
was heated at 60 °C for 1 h and cooled to 0 °C (ice-bath). Isonipecotic acid (75) (8.00 g,
61.93 mmol) was added and the reaction mixture was allowed to stir at room temperature
for 16 h. The solvent was removed by vacuum distillation to yield a white solid that was
recrystallized from i-PrOH to yield 6.00 g of 76 (66%) as a white solid: mp 136-138 °C
(lit.171 136-138 °C).

N-Formylpiperidine-4-carboxylic acid chloride (77).
In a 3-neck flask, SOCl2 (4.50 mL, 6.37 mmol) was added in a dropwise manner to a
stirred solution of compound 76 (5.00 g, 3.18 mmol) in DMF (0.6 mL) under an N2
atmosphere and cooled to 0 °C (ice-bath). The reaction mixture was allowed to stir at room
temperature for 6 h. SOCl2 was evaporated under reduced pressure to afford 5.00 g (90%)
of 1-formylpiperidine-4-carboxylic acid chloride (77) as a yellow-colored oil, which was
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verified spectrally and used without further characterization in the preparation of
compound 78.

N-Formyl-4-(2,4-difluorobenzoyl)piperidine (78).
In a 3-neck flask, AlCl3 (5.70 g, 4.27 mmol) was added to a stirred solution of compound
77 (5.00 g, 2.85 mmol) in 1,3-difluorobenzene (18 mL) and ClCH2CH2Cl (5 mL) under an
N2 atmosphere and the reaction mixture was heated at reflux for 45 h. The reaction mixture
was cooled to room temperature, quenched by the careful addition of ice/H2O (50 mL) and
extracted with CHCl3 (3 x 50 mL). The combined organic portion was washed with H2O (3
x 50 mL), brine (5 mL), dried (Na2SO4), and evaporated under reduced pressure to yield
3.00 g of a brown-colored oil, which was purified by column chromatography (silica gel;
hexanes/EtOAc; 0.4:0.6) to afford 0.75 g of a colorless oil which, when triturated with
petroleum ether, afforded 0.75 g (8%) of 78 as a white solid: mp 60-62 °C (lit.171 64-66
°C).

N-Formyl-4-((2,4-difluorophenyl)(hydroxyimino)methyl)piperidine (79).
In a 3-neck flask, compound 78 (0.50 g, 1.97 mmol) was added to a stirred solution of
hydroxylamine hydrochloride (0.41 g, 5.91 mmol) in EtOH (10 mL) under an N2
atmosphere. A solution of NaOH (0.24 g, 6.00 mmol) in H2O (1.5 mL) was added and the
reaction mixture was heated at reflux for 96 h. The reaction mixture was allowed to cool to
room temperature and filtered. The filtrate was evaporated under reduced pressure to yield
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a yellow-colored solid that was recrystallized from H2O to yield 0.42 g of 79 (79%) as a
white solid: mp 178-180 °C (lit.171 182-184 °C).

N-Formyl-4-(6-fluorobenz[d]isoxazol-3-yl)piperidine (80).
Toluene washed NaH (0.06 g, 2.50 mmol) was added to a stirred solution of compound 79
(0.20 g, 0.75 mmol) in anhydrous DMF (10 mL) and the stirred reaction mixture was
heated at 75 °C for 4 h. The reaction mixture was allowed to stir at room temperature for
48 h, quenched with H2O (25 mL) and extracted with EtOAc (3 x 20 mL). The combined
organic portion was washed with H2O (3 x 20 mL), brine (5 mL), dried (Na2SO4), and
evaporated under reduced pressure to yield 0.12 g of 80 (67%) as an orange oil. The
structure was verified spectrally and used crude in the preparation of compound 55. 1H
(CDCl3-d1): 1.80-1.89(m, 2H, CH2), 1.90-2.14(m, 2H, CH2), 2.45(s, 2H, CH2), 3.233.37(m, 2H, CH2), 3.74-3.77 (m, 1H, CH), 4.36-4.39(m, 1H, CHO), 6.99-7.02 (m, 1H,
ArH), 7.54-7.57 (m, 1H, ArH), 7.99-8.08 (m, 1H, ArH).

(2-Fluorophenyl)(1-methylpiperidin-4-yl)methanone (82).
In a 3-neck flask, 4-chloro-N-methylpiperidine (81) (1 g, 7.48 mmol) in anhydrous THF (3
mL) was added in a dropwise manner to a stirred mixture of Mg (0.23 g, 9.51 mmol) in
anhydrous THF (1 mL) and bromoethane (few drops) under an N2 atmosphere and the
reaction was initiated by a warm H2O bath. After complete addition of 4-chloro-Nmethylpiperidine (81), the reaction mixture was heated at reflux for 1 h, cooled to room
temperature and 2-fluorobenzonitrile (0.91 g, 7.48 mmol) in anhydrous THF (2 mL) was
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added. The reaction was heated at reflux for 3 h, the reaction mixture was allowed to stir at
room temperature for 36 h and quenched by addition of NH4Cl (2.93 g in 10 mL H2O). The
reaction mixture was heated on a H2O bath for 2 h, cooled to room temperature and
extracted with Et2O (3 x 20 mL). The combined organic portion was washed with H2O (3 x
15 mL), brine (5 mL), dried (Na2SO4) and evaporated to yield a brown-colored oil, which
was purified by column chromatography (silica gel; CHCl3:MeOH: 9.2:0.8) to yield a
brown-colored oil. The oil was dissolved in EtOH (5 mL) and cooled to 0 °C. A saturated
solution of gaseous HCl in Et2O (2 mL) was added to yield a orange-colored solid, which
was allowed to stir overnight with Et2O to yield 0.22 g (12%) of 82 as an orange solid: mp
162-166 °C (lit.171 167-169 °C).

Phenyl 4-(benz[d]isoxazol-3-yl)piperidine-1-carboxylate (83).
An aqueous solution of compound 61 (0.23 g, 0.91 mmol) was basified with NaOH (1M,
to pH 9) and extracted with toluene (4 mL). The organic portion was dried (Na2SO4),
filtered and added to a stirred solution of phenyl chloroformate under an N2 atmosphere.
The stirred reaction mixture was heated at reflux for 22 h, cooled to room temperature and
filtered. The filtrate was evaporated under reduced pressure to yield a yellow-colored oil.
The oil was dissolved in Et2O and petroleum ether was added to afford 0.15 g (52%)
compound 83 as a buff solid: mp 91-92 °C (lit.171 96-98 °C).
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3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,4(1H,3H)quinazolinedione hydrochloride (85).
Compound 95 (0.15 g, 0.79 mmol) was added to a stirred solution of 6-fluoro-3-(piperidin4-yl)benz[d]isoxazole (the free base of compound 55) (0.17 g, 0.79 mmol) in anhydrous
toluene (3.6 mL). The reaction mixture was allowed to stir in a screw-cap vial for 44 h at
100 °C. The excess toluene was removed under reduced pressure to yield a white-colored
solid. The solid was dissolved in HCl (12 N) and cooled to 0 °C. The solvent was removed
under reduced pressure to yield a white solid that was recrystallized from EtOH/H2O to
yield 0.05 g (27%) of 85 as a white solid: mp 268-270 °C. 1H NMR (DMSO-d6): 2.152.22 (m, 2H, CH2), 2.30-2.34 (m, 3H, CH2), 3.17-3.23 (m, 2H, CH2), 3.46-3.50 (m, 3H,
CH2), 3.87-3.90 (m, 2H, CH2), 4.32-4.33 (m, 2H, CH2), 7.23-7.25 (d, J = 8 Hz, 2H, ArH),
7.37-7.38 (d, J = 4 Hz, 1H, ArH), 7.69-7.74 (m, 2H, ArH), 7.97-7.99 (d, J = 8 Hz, 1H,
ArH), 8.11-8.14 (dd, J = 4, 8 Hz, 1H, ArH), 9.81 (br, s, 1H, NH+, D2O ex) Anal Calcd for
(C22H21FN4O3·HCl) C, 59.39; H, 4.98; N, 12.59. Found: C, 59.33; H, 5.14; N, 12.52.

4-(6-Fluoro-[1H]-indol-3yl)-1,2,3,6-tetrahydropyridine hydrogen oxalate (88).
6-Fluoroindole (96) (0.25 g, 1.85 mmol) was added to a stirred solution of 4-piperidone
monohydrate hydrochloride (0.72 g, 4.70 mmol) and KOH (0.55 g, 9.82 mmol) in
anhydrous MeOH (6 mL) under an N2 atmosphere. The stirred reaction mixture was heated
at reflux for 5 h, quenched by addition of H2O (25 mL) and allowed to stir at room
temperature overnight. The precipitate was collected by filtration, washed with H2O to
yield 0.20 g of a yellow-colored solid. The solid was dissolved in anhydrous MeOH (3
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mL) and the solution was cooled to 0 °C. A solution of oxalic acid (1 equivalent) in MeOH
was added and the reaction mixture was allowed to stir at room temperature overnight to
yield a yellow-colored solid, which upon recrystallization from EtOH/H2O afforded 0.03 g
(43%) of 88 as a yellow solid: mp 224 °C. 1H NMR (DMSO-d6): 2.61 (s, 2H, CH2), 3.203.23 (t, J = 4, 2H, CH2), 3.66 (s, 2H, CH2), 6.16 (s, 1H, CH), 6.89-6.94 (td, J = 4, 8, 1H,
ArH), 7.16-7.19 (dd, J = 12 Hz, 1H, ArH), 7.46-7.47 (d, J = 4 Hz, 1H, ArH), 7.79-7.83 (m,
1H, ArH), 11.27 ( s, 1H, NH+, D2O ex) Anal. Calcd for (C13H13N2F·0.5C2H2O4·0.25H2O)
C, 63.26; H, 5.49; N, 10.54. Found: C, 63.05; H, 5.43; N, 10.16.

6-Fluoro-3-(piperidin-4-yl)-1H-indole (89).
A saturated solution of gaseous HCl in EtOH (12 mL) was added to a stirred solution of
the free base of compound 88 (0.12 g, 2.312 mmol) in MeOH (12 mL). 10% Pd/C (0.018
g) was added and the reaction mixture was reduced in a Parr hydrogenator at 44 psi for 20
h. The reaction mixture was filtered and the filtrate was evaporated under reduced
pressure. The residue was dissolved in H2O (10 mL), the solution was basified with NaOH
(1N, to pH 8) and extracted with EtOAc (3 x 20 mL). The combined organic portion was
washed with H2O (3 x 10 mL), dried (Na2SO4) and evaporated under reduced pressure to
give a yellow-colored solid, which upon recrystallization from EtOH afforded 0.02 g
(15%) of 89 as a pale yellow-colored solid: mp 216-218 °C (lit.205 mp 214-216 °C) 1H
NMR (DMSO-d6): 1.54-1.65 (m, 2H, CH2), 1.87-1.89 (m, 2H, CH2), 2.66-2.73 (m, 2H,
CH2), 2.81-2.89 (m, 1H, CH), 3.07 (m, 2H, CH2), 6.79-6.84 (m, 1H, ArH), 7.06-7.12 (m,
2H, ArH), 7.53-7.57 (m, 1H, ArH), 10.90 (s, 1H, NH+, D2O ex).
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5-Methoxy-3-(piperidin-4-yl)benz[d]isoxazole hydrochloride (90).
Compound 101 (0.089 g, 0.55 mmol) was added to a stirred solution of HCl (12 N, 0.10
mL) and EtOH (5.0 mL) under an N2 atmosphere. The reaction mixture was heated at
reflux for 3 h and allowed to stand at room temperature for 48 h to afford a brown-color
oil. The oil was dissolved in EtOAc (2 mL) and the solution was cooled to 0 °C. A
saturated solution of HCl/Et2O was added and the reaction mixture was allowed to stir at
room temperature overnight. The precipitate was collected by filtration to yield a pale
yellow solid, which upon recrystallization from acetone afforded 0.012 g (13%) of 90 as an
off-white solid: mp 265-270 °C (lit.171 270-274 °C, MeOH/Et2O) 1H (DMSO-d6): 1.391.58 (m, 2H, CH2), 1.79-1.97 (m, 2H, CH2), 2.03 (s, 3H, OCH3), 2.70-2.76 (m, 1H, CH),
3.17-3.24 (m, 1H, CH2), 3.65-3.67 (m, 1H, CH2), 3.88-3.91 (m, 1H, CH2), 4.41-4.44 (m,
1H, CH2), 6.84 -6.86 (m, 1H, ArH), 7.01-7.03 (m, 1H, ArH), 7.26 (s, 1H, ArH), 9.20 (br s,
1H, NH+).

3-[2-[4-(6-Fluoro[1H]indol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride (91).
In

a

2-neck

flask,

3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-

a]pyrimidin-4-one (92) (0.20 g, 0.88 mmol) and compound 89 (0.19 g, 0.88 mmol) were
added to a stirred solution of K2CO3 (0.12 g, 0.882 mmol) and KI (few crystals) in
anhydrous MeCN (18 mL) under an N2 atmosphere. The stirred reaction mixture was
heated at reflux for 45 h, cooled to room temperature and the solvent was evaporated under
reduced pressure. The residue was suspended in H2O and extracted with CHCl3 (3 x 50
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mL). The combined organic portion was washed with H2O (3 x 50 mL), dried (Na2SO4)
and evaporated under reduced pressure to yield a yellow-colored solid. The solid was
dissolved in anhydrous Et2O (2 mL) and cooled to 0 °C. A saturated solution of gaseous
HCl in Et2O (2 mL) was added and the reaction mixture was allowed to stir at room
temperature overnight. The precipitate was collected by filtration to yield a yellow-colored
solid, which upon recrystallization from EtOH/H2O afforded 0.05 g (37%) of 91 as a
yellow solid: mp 279-281 °C. 1H (DMSO-d6): 1.62-1.68 (m, 2H, CH2), 1.68-1.79 (m, 2H,
CH2), 1.83-1.94 (m, 4H, CH2), 2.11-2.16 (m, 2H, CH2), 2.21(s, 3H, CH2), 2.36-2.40 (m,
2H, CH2), 2.59-2.63 (m, 2H, CH2), 2.74-2.78 (m, 3H, CH2), 3.01-3.04 (m, 2H, CH2), 3.773.80 (t, J = 4 Hz, 2H, CH2), 6.78-6.84 (m, 1H, ArH), 7.08-7.11(m, 2H, ArH), 7.51-7.54
(dd, J = 4 Hz, 1H, ArH), 10.37 (br, s, 1H, NH+, D2O ex), 10.98 (s, 1H, NH, D2O ex) Anal.
Calcd. for (C24H29N4OF·2HCl·0.5H2O) C, 58.77; H, 6.57; N, 11.42 Found: C, 58.78; H,
6.61; N, 11.22.

3-(2-(1-Piperidinyl)ethyl)-2,4(1H,3H)-quinazolinedione hydrochloride (94).
Compound 95 (0.10 g, 0.54 mmol) was added to piperidine (68) (3 mL) and the stirred
reaction mixture was heated at reflux for 4 h. The excess piperidine was removed under
reduced pressure to yield a tan-colored solid. The solid was dissolved in anhydrous Et2O (5
mL) and cooled to 0 °C. A saturated solution of gaseous HCl in Et2O (2 mL) was added
and the reaction mixture was allowed to stir at room temperature overnight. The precipitate
was collected by filtration to yield a white solid that was recrystallized from absolute
EtOH to yield 0.06 g (75%) of 94 as a white solid: mp 274-276 °C (lit.143 276-278 °C). 1H
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NMR (DMSO-d6): 1.38-1.44 (m, 1H, CH2), 1.62-1.85 (m, 3H, CH2), 1.82-1.85 (m, 2H,
CH2), 2.90-2.98 (m, 2H, CH2), 3.34-3.35 (m, 2H, CH2), 3.62-3.65 (m, 2H, CH2), 4.25- 4.28
(m, 2H, CH2), 7.22-7.26 (m, 2H, ArH), 7.68-7.72 (t, J = 8 Hz, 1H, ArH), 7.95-7.97 (d, J =
8 Hz, 1H, ArH), 9.38 (br s, 1H, NH+, D2O ex), 11.60 (s, 1H, NH+, D2O ex).

2,3-Dihydro-5H-oxazolo[2,3-b]quinazolin-5-one (95).
3-(2-Chloroethyl)-2,4(1H,3H)quinazolinedione (93) (0.30 g, 1.33 mmol) was added to a
stirred solution of K2CO3 (0.18 g, 1.33 mmol) in anhydrous acetone (9 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature and evaporated
under reduced pressure. The residue was suspended in H2O and extracted with CH2Cl2 (3 x
10 mL). The combined organic portion was washed with H2O (3 x 10 mL), dried (Na2SO4)
and evaporated to dryness under reduced pressure to yield 0.19 g (77 %) of 95 as a white
solid: mp 159-162 °C (lit.143 160-162 °C), which was used without further purification in
the preparation of compounds 85 and 94.

1-Acetylpiperidine-4-carboxylic acid (97).
A stirred solution of isonipecotic acid (75) (8.0 g, 61.93 mmol) and EtOAc (24 mL) was
cooled to 0 °C (ice-bath). Then Ac2O (8.7 mL, 92.89 mmol) was added and the reaction
mixture was allowed to stir at 5 °C for 0.16 h. The stirred reaction solution was heated at
60 °C for 2 h and cooled to room temperature. The precipitate was collected by filtration,
washed with diisopropyl ether to yield 10.2 g of 97 (96%) as a white solid: mp 182-184 °C
(lit.171 180-182 °C), which was used crude in the preparation of compound 98.
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1-Acetylpiperidine-4-carboxylic acid chloride (98).
In a 3-neck flask, SOCl2 (61 mL, 6.37 mmol) was added to a stirred solution of 97 (10.0 g,
58.41 mmol) in ClCH2CH2Cl (24 mL) under an N2 atmosphere and the reaction mixture
was allowed to stir at room temperature for 6 h. The precipitate was collected by filtration
to yield 10.50 g of 98 (95%) as a white solid: mp 138-140 °C (lit.171 133-138 °C), which
was used crude in the preparation of compound 99.

1-Acetyl-4-(2-hydroxy-5-methoxybenzoyl)piperidine (99).
In a 3-neck flask, AlCl3 (14.06 g, 105.46 mmol) was added to a stirred solution of
compound 98 (1.00 g, 52.73 mmol), 1,3-dimethoxybenzene (7.28 g, 52.73 mmol) and
ClCH2CH2Cl (5 mL) under an N2 atmosphere and the reaction mixture was heated at reflux
for 45 h. The reaction mixture was cooled to room temperature, quenched by the careful
addition of ice/H2O (50 mL) and the aqueous portion was extracted with CHCl3 (3 x 50
mL). The combined organic portion was washed with H2O (3 x 50 mL), brine (5 mL),
dried (Na2SO4), and evaporated under reduced pressure to yield a pale yellow-colored oil
which, when triturated with petroleum ether, afforded a pale yellow solid, which upon
recrystallization with EtOH yielded 0.20 g (13%) of 99 as a yellow solid: mp 93-95 °C
(lit.171 93-94 °C).
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1-Acetyl-4-((2-hydroxy-5-methoxyphenyl)(hydroxyimino)methyl)piperidine (100).
In a 3-neck flask, 99 (0.20 g, 3.61 mmol) was added to a stirred solution of hydroxylamine
hydrochloride (0.29 g, 4.26 mmol) in EtOH (16 mL) under an N2 atmosphere. A solution
of NH4OAc (0.61 g, 7.94 mmol) in H2O (4.80 mL) was added and the reaction mixture
was heated at reflux for 36 h. The reaction mixture was allowed to cool to room
temperature and filtered. The filtrate was evaporated under reduced pressure to yield a
yellow-colored solid that was recrystallized from H2O to yield 0.12 g of 100 (54%) as a
yellow solid: mp 196-200 °C (lit.171 193-196 °C), which was converted to the acetate salt:
mp 208-210, and used crude in the preparation of compound 101.

1-Acetyl-4-(5-methoxybenz[d]isoxazol-3-yl)piperidine (101).
Toluene-washed NaH (0.011 g, 0.463 mmol) was added to a stirred solution of the acetate
salt of compound 100 (0.15 g, 0.42 mmol) in anhydrous DMF (2 mL) and the stirred
reaction mixture was heated at reflux for 6 h. The reaction mixture was allowed to stir at
room temperature for 24 h, quenched by pouring in H2O (25 mL) and the reaction mixture
was extracted with EtOAc (3 x 20 mL). The combined organic portion was washed with
H2O (3 x 20 mL), brine (5 mL), dried (Na2SO4), and evaporated under reduced pressure to
yield 0.09 g of 101 (81%) as a brown oil, which was verified spectrally and used crude in
the preparation of compound 90.
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B. Molecular modeling studies:
The primary sequence of the human 5-HT2A receptor was obtained from the Universal
Protein Resource (UniProt) (entry code: P28223; Homo sapiens) in the FASTA format.
The amino acid sequence of the crystal structure of the 5-HT2B receptor (PDB ID: 4IB4)
was retrieved from the Protein Data Base (PDB). During crystallization, residues Y249V313 (ICL3) of the 5-HT2B receptor were replaced with A1-L106 of BRIL.187,206 These
residues were deleted\ from the amino acid sequence file of the crytal structure of the
5-HT2B receptor prior to sequence alignment. Multiple sequence alignment of the 5-HT2B
receptor amino acid sequence with the 5-HT2A receptor sequence was performed with the
software ClustalX2.0, which provided output in the form of .ps, .aln and .dnd files. One
hundred homology models of the 5-HT2A receptor were generated using the software
package Modeller 9.12207 (version 9.12; University of California San Francisco, San
Francisco, CA). Modeller processes the sequence alignment in the form of the .ali format,
which, along with the sequence alignment also includes details about the template, and the
protein of interest.

The model for comparing the binding pocket of the receptor to previously published 5HT2A homology models was chosen based on the discrete optimized protein energy
(DOPE) scores and the models were further examined by docking studies of ketanserin.

The ligands were built using the sketch feature within SYBYL-X 2.1 (Tripos International,
St. Louis, MO, USA), and were energetically minimized using the Tripos Force Field
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[Gasteiger-Hückel charges, the dielectric constant (ε) = 4, the non bonded interaction
cutoff = 8 Å and was terminated at an energy gradient of 0.05 kcal/(mol*Å)] feature within
SYBYL-X 2.1.

Molecular docking was performed using the GOLD scoring function within the genetic
algorithm docking program GOLD208 (Version 5.3; Cambridge Crystallographic Data
Centre, Cambridge, UK). The binding pocket was defined to include all atoms within 10-Å
of the α-carbon atom of the highly conserved D155 (TM3). The docking solutions were
sorted by cluster docking (the script was provided by Dr. Philip D. Mosier) and examined
on SYBYL-X 2.1) The models chosen (based on binding interactions and their GOLD
scores) were merged with the ligands and energetically minimized using the Tripos Force
Field (Gasteiger Hückel charges, distance-dependent dielectric constant = 4.0). The models
were further evaluated by HINT analysis194 (as implemented within SYBYL 8.1) to
quantify the ligand-receptor interactions and the model with the highest HINT scores was
chosen for every ligand under the study. PyMOL was used to generate images.209

C. Functional activity studies:
a. Calcium imaging epifluorescence assay:
Measurements of Intracellular Ca2+
Cells (HEK293 cells) were plated on 96-well dishes the day before the experiment. The
next day cells were switched to serum-free medium for about 3-4 hours, before being
loaded with 5 µm Fura2-AM (Molecular Probes, OR) in Imaging Solution (125 mM NaCl,
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5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 6 mM glucose, and 25 mM Hepes/Tris, pH 7.4).
Following incubation for 30 min at 37oC, cells were washed with imaging solution and
kept at room temperature for about 15 min before being placed on the stage of an
epifluorescence microscope, coupled to an automatic perfusion system.

The Fura-2 signal was acquired at 510 nm by switching the excitation wavelength between
340 nm and 380 nm. Intracellular calcium concentration was expressed as a 340/380 nm
ratio and values were normalized to the basal 340/380 nm ratio level before perfusion of
the drug. Results were expressed as mean ± SEM. Statistical significance was determined
by two-tailed Student’s t test. IC50 values are obtained by analysis in GraphPad PRISM
(version 6.00 for Mac OS X, GraphPad Software, La Jolla California, US).210

b. Electrophysiology studies:
The electrophysiological functional assay studies were conducted in the Xenopus laevis
heterologous oocyte system expressing the 5-HT2A and the GIRK4* channels. After they
were enzymatically isolated, the oocytes were microinjected with 1-2 ng cRNA constructs.
The oocytes were then incubated for 2 days at 18 °C for expression. Responses were
recorded by conventional two-electrode voltage clamp (TEVC) assay with a
GeneClamp500 amplifier (Axon Instruments) 3-5 days after cRNA injection. A high
potassium concentration solution containing 96 KCl, 1NaCl, MgCl2, 5 KOH/HEPES, in
mM) was used to record basal channel expression levels and a 3mM BaCl2 was used to
block the GIRK4* currents.173
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D. Radioligand binding studies:
The radioligand binding studies were performed in HEK293 cells transiently transfected
with the N-terminally c-Myc-tagged form of wild type human 5-HT2A receptor
(pcDNA3.1-c-Myc-5HT2A) using Lipofectamine 2000 reagent (Invitrogen). The cell
pellets were homogenized using a Teflon-glass grinder (10 up-and-down strokes at 1500
rpm) after 48 hours in 1 mL of binding buffer (50 mM Tris-HCl, pH 7.4), supplemented
with 0.25 M sucrose. The crude homogenate was centrifuged at 1000 g for 5 min at 4 °C,
and the supernatant was centrifuged at 40,000 g for 15 min at 4 °C. The resultant pellet (P2
fraction) was washed twice in homogenization buffer and re-centrifuged in similar
conditions. Aliquots were stored at 80 °C until assay. Curves were carried out by
incubating each drug (10-10–10-4 M; 13 concentrations) in binding buffer containing 2 nM
[3H]-ketanserin. Nonspecific binding was determined in the presence of 10 µM
methylsergide (Tocris). Competition curves were analyzed by nonlinear regression by
GraphPad PRISM (version 6.00 for Mac OS X, GraphPad Software, La Jolla California,
US) to derive dissociation constants for high (Ki-high) and low (Ki-low) affinity states of the
receptor211 that were reported only as a single Ki value in Tables/Figures. The equation for
the curve fitting: log EC50 = log (10^log Ki*(1 + Radioligand NM/HotKd NM)
Y = Bottom + (Top - Bottom)/(1 + 10 ^ (X-logEC50)).
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Appendix A

After the dissertation had been written, additional data on the activity of risperidone and
compounds 56 and 57 at the GIRK4* channel in the presence and the absence of the

GIRK4* current inhibition
(% Normalized to 1 µM 5-HT)

5-HT2A receptor in the TEVC assay system were obtained.

5"HT2A'

Risperidone (3)

Figure A1. Inhibitory action of risperidone (3) at the GIRK4* channel in the presence and
the absence of the 5-HT2A receptor in the TEVC assay. (N = 4/condition). Data are mean ±
SEM, *p < 0.05, experiments were replicated in a second batch of oocytes.
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GIRK4* current inhibition
(% Normalized to 1 µM 5-HT)

5"HT2A'

56
Figure A2. Inhibitory action of compound 56 at the GIRK4* channel in the presence and
the absence of the 5-HT2A receptor in the TEVC assay. (N = 4/condition). Data are mean ±
SEM, *p < 0.05, experiments were replicated in a second batch of oocytes.
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GIRK4* current inhibition
(% Normalized to 1 µM 5-HT)

5"HT2A'

57

Figure A3. Inhibitory action of compound 57 at the GIRK4* channel in the presence and
the absence of the 5-HT2A receptor in the TEVC assay. (N = 4/condition). Data are mean ±
SEM, *p < 0.05, experiments were replicated in a second batch of oocytes.

Risperidone (3) was tested at concentrations of 30, 50 and 100 µM (Figure A1), compound
56 was studied at 30 and 50 µM (Figure A2), and compound 57 was tested at 5, 10, 30 and
50 µM (Figure A3). All three compounds showed comparable agonist activity at the
GIRK4* channel in the presence and absence of the 5-HT2A receptor. This suggests that
the positive efficacy shown by compounds 56 and 57 in the TEVC assay (Figure 27A)
could be due to their activity at the GIRK4* channel instead of Gαq-mediated activity at the
5-HT2A receptor.

The activity seen with compound 57 at 50 µM in Figure 27B was comparable to its activity
at GIRK4* in the absence of the 5-HT2A receptor when studied at 50 µM (Figure A3). The
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above information coupled with the high binding affinity of compound 57 at the receptor
(Figure 30 and Table 4) imply that compound 57 might not be a superagonist or an agoallosteric modulator as speculated earlier, and that the 5-HT- potentiating activity seen at
the concentration of 50 µM (Figure 27B) could be solely due to its activity at the GIRK4*
channel. As a consequence, the IC50 values shown in Table 4 for the TEVC assay might
not be valid.
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